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5ABSTRACT
Lyme borreliosis  (LB)  (also  known as  Lyme disease)  is  a  bacterial  infection
spread  by  the  bite  of Ixodes sp.  ticks.  The  disease  is  caused  by Borrelia sp.
spirochaetes (Borrelia burgdorferi sensu lato), a group of at least 20 species
or genospecies, though less than ten species are known to be pathogenic for
humans. Distribution of B. burgdorferi sensu  lato species varies
geographically, with Lyme borreliosis found in Europe, Asia and Northern
America.
The  typical  initial  manifestation  of  LB  is  a  ring-like  rash,  erythema
migrans (EM), found around the tick bite site after a couple of days or weeks.
The  patient  may  not  notice  either  the  tick  bite  or  EM  rash.  Later
manifestations  may  appear  within  weeks,  months  or  sometimes  even  after
years.  Manifestations of  later  stages of  LB are other skin related symptoms,
Lyme arthritis (LA), cardiac symptoms, or manifestations in the central
nervous system (neuroborreliosis (LNB) manifesting as meningoradiculitis
or meningitis).
EM  is  the  only  manifestation  of  LB  which  can  be  used  as  a  basis  of  a
reliable clinical diagnosis. All other manifestations are not pathognomonic to
LB  and  have  to  be  confirmed  with  laboratory  tests  performed  either  on
serum, CSF samples, or both. PCR or culture of Borrelia spirochaetes from
patient  samples  are  no  longer  recommended  for  routine  laboratory
diagnostic methods. Cultivation of Borrelia from  patient  samples  has  very
low sensitivity.  Laboratory testing is  based on detection of Borrelia specific
antibodies, usually with an ELISA method and immunoblotting (know as 2-
tier testing). Tests currently in use have some problems with sensitivity and
specificity. Anti-Borrelia antibodies are not always detectable and antibody
responses may persist for years after treatment of the disease. There are no
markers  of  active  disease.  Antibodies  to  some  other  diseases  can  also
interfere with immunological assays resulting in false positive test results.
Re-testing of patients is needed in some cases after a couple of weeks.
The aim of this study was to identify more sensitive and specific antigens
for  the  laboratory  diagnostics  of  LB.  A  large  amount  of  serum  and  CSF
samples were collected from patients with different manifestations of LB
(EM, LNB, LA) from Europe and the United States. Five IR6 peptide variants
(IR6  is  invariable  region  6  of  the  VlsE  protein)  as  antigens  were  evaluated
together with one commercial C6 Immunoassay in serodiagnosis of early and
disseminated stages of LB.  Recombinant decorin binding protein A (DbpA)
and  B  (DbpB)  (three  variants  of  each)  as  antigens  were  evaluated  in
serodiagnosis of LNB. CXCL13 Immunoassay was used to measure
chemokine CXCL13 levels in children with early LNB.
The sensitivity of IR6 peptide variant ELISAs varied in patients
presenting with different stages of LB from Europe or the United States. IR6
6peptide ELISAs reached approximately the same sensitivity level in IgG tests
as the C6 Immunoassay with patient samples from disseminated cases (LNB,
LA).  With  early  manifestations  (EM),  the  overall  sensitivity  of  IR6  ELISAs
combined was better than that of the C6 Immunoassay. In addition, some of
the samples negative in the C6 Immunoassay were positive with IR6 peptide
assays. The sensitivity of IR6 peptide IgM tests was better in patient samples
from the United States than in European samples, even though the sensitivity
remained significantly lower than that of the IR6 peptide IgG tests.
In the laboratory diagnostics of LNB, antibody testing to DbpA was found
to be more sensitive than that to DbpB. The sensitivity of DbpB ELISAs was
significantly  lower  in  children  than  in  adults.  This  was  probably  due  to  the
shorter  duration  of  LNB  in  children  and  therefore  undetectable  levels  of
Borrelia-specific antibodies. Chemokine CXCL13 levels in the CSF were high
in patients with confirmed LNB. The CXCL13 levels were detectable earlier
than Borrelia-specific antibodies in the CSF.
In  conclusion,  the  use  of  several  IR6  peptide  variants  originating  from
different Borrelia species  in  one  assay  may  improve  the  laboratory
diagnostics of LB by increasing the sensitivity of a test. DbpA and DbpB may
serve as supplementary antigens in diagnostic assays, especially when a
combination of several species-specific variants is used. Appearance of
CXCL13  in  the  CSF  seems  to  be  an  early  immunological  marker  of
inflammation  in  CNS  and  measurement  of  CXCL13  concentrations  in  the
CSF may improve the diagnostics of LNB.
7TIIVISTELMÄ
Lymen  borrelioosi  (Lymen  tauti)  on Ixodes sp. –suvun puutiaisten
(”punkkien”) pureman välityksellä leviämä bakteeri-infektio. Lymen
borrelioosia ihmisille aiheuttavia Borrelia-suvun spirokeettabakteereita
tunnetaan kahdeksan ja kokonaisuudessaan ryhmään kuuluu jo 20 eri
tieteellisesti kuvattua lajia. Ryhmästä käytetään usein nimitystä Borrelia
burgdorferi sensu lato. Lymen borrelioosia aiheuttavia Borrelia-bakteereita
tavataan ainakin Euroopasta, Aasiasta ja Pohjois-Amerikasta ja B.
burgdorferi sensu lato lajien levinneisyys vaihtelee eri alueilla.
 Taudille tyypillinen ensioire on rengasmainen ihottuma (erythema
migrans) puutiaisen puremakohdan ympärillä ilmaantuen muutaman päivän
tai viikon kuluttua puremasta. Tosin kaikille potilaille tätä oiretta ei tule tai
kaikki eivät huomaa puutiaisen puremaa tai siitä seurannutta ihottumaa ja
ilman antibioottihoitoa tauti voi päästä etenemään. Myöhäisoireet
ilmaantuvat useiden viikkojen tai kuukausien päästä, joskus jopa vuosien
päästä. Myöhäisoireita ovat muiden muassa erilaiset iho-oireet, erilaiset
sydänoireet sekä niveloireet kuten artriitti (LA), tai keskushermosto-oireet
kuten meningiitti neuroborrelioosissa (LNB).
Erythema migrans (EM) on ainoa taudin kliinisistä oireista, jonka
perusteella diagnoosi voidaan tehdä ilman laboratoriotutkimuksia. Kaikissa
muissa tapauksissa kliininen diagnoosi on varmistettava verestä tai aivo-
selkäydinnesteestä (tai molemmista) tehtävillä laboratoriokokeilla.
Laboratoriodiagnostisiin menetelmiin kuuluu Borrelia-spesifisten vasta-
aineiden osoittaminen näytteistä yleensä ELISA-menetelmällä sekä
immunoblottauksella. Geenimonistusta PCR-reaktion avulla tai bakteerin
osoittamista viljelemällä potilasnäytteistä ei enää suositella Lymen
borrelioosin rutiinidiagnostiikkaan. Borrelia-bakteerin osoittamisessa
viljelyn avulla potilasnäytteistä on ongelmana hyvin alhainen saanto. Lymen
borrelioosin laboratoriodiagnostisten menetelmien ongelmana on ollut
niiden alhainen herkkyys (sensitiviteetti) ja tarkkuus (spesifisiteetti).
Borrelia-spesifiset vasta-aineet eivät ole aina mitattavissa ja vasta-ainetasot
säilyvät välillä pitkään hoidetun infektion jälkeen. Testien avulla aktiivisen
infektion erottaminen jo sairastetusta infektiosta on välillä haastavaa. Vasta-
aineet muita infektioita kohtaan voivat myös näkyä väärinä positiivisina
tuloksina Lymen borrelioosin testituloksissa.
Tutkimuksen tavoitteena oli löytää herkempiä ja tarkempia antigeenejä
käytettäviksi Lymen borrelioosin laboratoriodiagnostiikassa. Suurehko
määrä seerumi- ja likvorinäytteitä kerättiin Euroopasta ja Yhdysvalloista
tutkimuskäyttöön Lymen borrelioosipotilailta, joilla oli erilaisia oireita (EM,
LNB, LA). Tutkittavana olleet antigeenit olivat IR6-peptidit (5 erilaista) sekä
dekoriinia  sitovat  proteiinit  A  ja  B  (DbpA  ja  DbpB)  (3  erilaista
kummastakin). Näiden rinnalla testattiin pari kaupallista sovellusta, C6
8Immunoassay ja CXCL13 Immunoassay, joka mittaa kemokiini CXCL13
konsentraatiota näytteessä.
IR6-peptidivarianttien vasta-ainetasot vaihtelivat eri potilasryhmien
välillä. Potilasryhmät edustivat Lymen borrelioosin eri vaiheita ja potilaita oli
sekä Euroopasta että Yhdysvalloista. Taudin myöhäisvaiheita edustaneiden
näytteiden kohdalla (neuroborrelioosi, artriitti) IR6-peptiditestien herkkyys
oli yhtä hyvä C6 Immunoassayn kanssa. Kun viiden eri IR6-peptidin tuloksia
tarkasteltiin yhdistettynä, oli testi tarkempi kuin C6 Immunoassay EM-
potilaiden diagnostiikassa. IgM-testin herkkyys oli parempi yhdysvaltalaisten
kuin eurooppalaisten potilasnäytteiden kanssa, vaikkakin herkkyys jäi
huomattavasti IgG-testiä alhaisemmaksi.
DbpA osoittautui paremmaksi antigeeniksi kuin DbpB
neuroborrelioosipotilaiden diagnostiikassa. DbpB-testi oli huomattavasti
heikompi lapsipotilaiden kuin aikuisten diagnostiikassa. Tämä johtuu
todennäköisesti siitä, että lapsilla taudin kesto ennen hoitoon hakeutumista
on lyhyempi ja täten Borrelia-spesifisiä vasta-aineita ei vielä ollut mitattavia
määriä näytteissä. Kemokiini CXCL13 -pitoisuudet olivat korkeita
neuroborrelioosipotilailla. CXCL13-pitoisuudet näyttävät olevan mitattavissa
aiemmin kuin Borrelia-spesifiset vasta-aineet.
Yhteenvetona tämän väitöskirjatyön tuloksista: useiden IR6-peptidien
käyttö samassa testissä voi parantaa Lymen borrelioosin
laboratoriodiagnostiikkaa. Dekoriinia sitovat proteiinit DbpA ja DbpB
voisivat olla hyvä lisä johonkin testiin, erityisesti useamman erilaisen
rekombinanttiproteiinin yhdistelmänä. Kemokiini CXCL13 näyttää olevan
varhainen merkki neurologisesta infektiosta ja CXCL13-pitoisuuden
mittaaminen voi parantaa sekä lasten että aikuisten akuutin
neuroborrelioosin diagnostiikkaa.
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ABBREVIATIONS
ACA acrodermatitis chronica atrophicans
ANA+ anti-nuclear antibodies positive
ASO+ anti-streptolysin antibodies positive
BamA Borrelia burgdorferi outer membrane protein ortholog of the β-
barrel assembly machine (BAM)
BBA64 lipoprotein of 35 kDa
BBB Blood-brain barrier
BbCRASP complement regulator acquiring surface protein of Borrelia
burgdorferi
BBK32 fibronectin binding protein, binds also glycosaminoglycan
BB0405 surface-localized transmembrane-spanning outer membrane
protein; function unknown
BD healthy blood donor
BptA borrelial persistence in ticks A, outer surface protein
C4bp C4b (part of complement system) binding protein
C6 commercial name for IR6 peptide
C6 IH In-house cut-off value for the C6 Immunoassay
CD59 protectin, inhibitor of membrane-attack complex (MAC)
CDC Centers for Disease Control and Prevention of the United States
of America
CNS central nervous system
CRASP complement regulator acquiring surface protein; 5 proteins
currently known
CSF cerebrospinal fluid
CspA other name for CRASP-1 protein
CXCL13 chemokine targeting naive B cells and immature dendritic cells
among others
Dbp decorin binding protein
DNA deoxyribonucleic acid
EIA enzyme immunoassay
ELISA enzyme linked immunosorbent assay
EM erythema migrans
ErpX surface-exposed outer membrane protein X, binds to laminin
GAG glycosaminoglycan
HPLC high pressure liquid chromatography
IFA immunofluorescent antibody assay
IgG immunoglobulin G
IgM immunoglobulin M
IPTG isopropyl-β-D-thiogalactoside
IR invariable region
IR6 26 amino acids long peptide, invariable region 6 of protein VlsE
13
kDa kilodalton, dalton is a unit of a molecular weight
LA Lyme arthritis
LB Lyme borreliosis
LNB Lyme neuroborreliosis
Lmp1 surface-located membrane protein 1
lp linear plasmid
Lp6.6 lipoprotein 6.6 of 6.6 kDa
NOD nucleotide binding oligomerization domain
OD optical density
Omps outer membrane proteins
Osp outer surface (lipo)proteins
P1 peptide  1,  IR6  region  of  VlsE  protein  of Borrelia burgdorferi
sensu stricto
P2 peptide 2, IR6 region of VlsE protein of Borrelia garinii IP90
P3 peptide 3, IR6 region of vls recombination cassette 3 of Borrelia
afzelii ACA-I
P4 peptide 4, IR6 region of vls recombination cassette 4 of Borrelia
afzelii ACA-I
P5 peptide 5, IR6 region of vls recombination cassette 9 of Borrelia
afzelii ACA-I
P13 integral membrane porin protein of 13 kDa
P66 integral membrane porin protein of 66 kDa, same as Oms66
PBS phosphate buffered saline
PCR polymerase chain reaction
PLDS post-Lyme disease syndrome
RE restriction enzyme
RevA borrelial outer surface protein of 17 kDa, binds fibronectin
RevB borrelial outer surface protein of 20 kDa, binds fibronectin
RF+ rheumatoid factor positive
Salp15 tick salivary gland protein 15 of 15 kDa
SDS-PAGE sodium dodecyl sulphate - polyacrylamide gel electrophoresis
ss sensu stricto
WB Western blotting
vls variable major protein like sequence
VlsE borrelial outer surface protein of 35 kDa
Vmp variable major protein
VR variable region
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1 INTRODUCTION
Lyme borreliosis (LB; also Lyme disease) is one of the tick-borne diseases
whose incidence has increased in endemic areas during the past two decades
(Kilpatrick & Randolph 2012). In this same period of time, this vector-borne
disease  has  appeared  in  new  regions  due  to  both  environmental  factors
affecting the abundance of Ixodes sp.  ticks  and  wildlife  hosts,  along  with
continuous  research  on  the  distribution  and  taxonomy  of Borrelia sp.
spirochaetes  (Kilpatrick  &  Randolph  2012;  Franke  et  al.  2013).
Taxonomically, the number of Borrelia species and strains belonging to the
Lyme borreliosis group has increased from the three species recognized in
Europe  (B. burgdorferi sensu stricto, B. garinii, and B. afzelii) and  one  in
North  America  (B. burgdorferi sensu  stricto)  in  the  1980s  up  to  a
heterogeneous complex of twenty scientifically reported species at present
(see Figure 4 for detailed information) (Margos et  al.  2011;  Stanek & Reiter
2011; Ivanova et al. 2013). The species which cause the disease in humans are
commonly referred to as B. burgdorferi sensu lato.
Diagnostics of LB remains challenging. With the exception of erythema
migrans (EM), clinical manifestations are not disease specific and laboratory
tests are required to confirm the diagnosis of LB (Stanek et al. 2012). Culture
of Borrelia spirochaetes has low sensitivity and culture together with
polymerase chain reaction (PCR) is no longer recommended for the routine
laboratory  diagnostics  of  LB  (Wilske  et  al.  2007;  Stanek  et  al.  2012).
Laboratory diagnostics is commonly performed by 2-tier testing, which is the
confirmation of a positive test by another test (Wormser et al. 2006; Wilske
et  al.  2007;  Stanek  et  al.  2012).  Sometimes  follow-up  samples  are  needed
after  a  week  or  two  due  to  a  delay  in  the  development  of  pathogen-specific
antibodies (Wilske et  al.  2007).  Of the EM patients,  only 20-50% may have
detectable amounts of antibodies in traditional flagella assay (Hansen &
Asbrink 1989). Interpretation of laboratory test results should be done in
context  of  the  patient’s  clinical  data,  as  antibody  levels  measured  by  the
currently available diagnostic methods do not indicate the disease status
(active  infection  or  antibodies  from  an  earlier,  already  cured  infection)
(Wilske et al. 2007).
This thesis focuses on the laboratory diagnostics of LB and on the use of
new recombinant borrelial protein and peptide variants as antigens in the
diagnostic  laboratory  assays.  The  main  aim  of  these  studies  has  been  the
improvement of laboratory diagnostics of different manifestations of LB.
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2 REVIEW OF THE LITERATURE
The aims of this literature review are to provide insight into Lyme borreliosis
as  a  clinically  and  by  laboratory  methods  diagnosed  disease  as  well  as  to
cover the microbiological and ecological aspects of tick-borne Borrelia sp.
spirochaetes causing this infection.
2.1 HISTORY OF LYME BORRELIOSIS
Lyme borreliosis is named after the town Old Lyme, Connecticut, USA, where
an arthritis-type disease appeared in many of its residents, especially
children,  in  the  1970s.  This  disease,  or  an  epidemic  form  of  arthritis  (as  it
was  referred  to  at  that  time),  was  scientifically  reported  in  1977  by  Allen
Steere (Steere et al. 1977). The first publication known relating to the disease
LB  is  Buchwald’s  description  of  a  chronic  skin  disorder  (later  named
acrodermatitis  chronica  atrophicans  (ACA))  in  1883  (Buchwald  1883).  The
Swedish  scientist  Afzelius  presented  a  patient  with  a  slowly  expanding  skin
lesion erythema migrans (EM) in 1909 (Afzelius 1910). In Europe, the disease
was known as a group of disorders (EM, lymphocytoma, and ACA) associated
with the bite of Ixodes ticks (Weber et al. 1984). The search for the causative
agent of LB went on until the early 1980s when William Burgdorfer was able
to isolate spirochetes from I. scapularis ticks  and  those  spirochetes  were
shortly after confirmed to be the causitive agent of LB by other researchers
(Burgdorfer et al. 1982; Barbour et al. 1983; Benach et al. 1983; Steere et al.
1983).
Researchers  in  Europe  also  reported  on  spirochaetes  isolated  from ticks
and  from  the  skin  and  cerebrospinal  fluid  of  patients  (Asbrink  &  Hovmark
1985; Stanek et al. 1985; Preac-Mursic et al. 1986). It was later confirmed
that  the  European  and  North  American  diseases  were  the  same  and  the
spirochete received its scientific name Borrelia burgdorferi after William
Burgdorfer  (Johnson  et  al.  1984).  The  coexistence  of B. burgdorferi and
humans has been shown to have lasted for a long time: Metagenomic analysis
performed  on  the  remains  of  the  Tyrolean  Iceman  “Ötzi”  (a  5300  year  old
body found from the Italian Alps in 1991) revealed DNA sequences covering
60% of the genome of B. burgdorferi (Keller et al. 2012).
2.2 LIFE CYCLE OF BORRELIA SPIROCHAETES IN
NATURE
The  life  cycle  of  LB  spirochaetes  involves  ticks  from Ixodes ricinus species
complex  as  vectors  and  a  variety  of  mammalian,  avian,  and  reptile  hosts
Review of the literature
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(Piesman & Gern 2004; Tilly et al. 2008; Bouchard et al. 2011; Margos et al.
2011;  Takano  et  al.  2011;  Brisson  et  al.  2012).  The  primary  vectors  of B.
burgdorferi sensu lato spirochaetes (Borrelia species pathogenic to humans)
are I. ricinus (most parts of Europe), I. scapularis and I. pacificus (North
America) and I. persulcatus (Asia), but there are several other Ixodes sp. tick
species  and  ticks  and  lice  from  other  genera  (Hyalomma, Amblyomma,
Dermacentor, Haemaphysalis, Aedes, Ornithodoros, Culex, Rhipicephalus,
Boophilus, and Ctenophthalmus)  that  may  also  spread  these  spirochaetes
(Masuzawa 2004; Piesman & Gern 2004; Franke et al. 2013).
The  life  cycle  of Ixodes ticks  involves  egg,  larva,  nymph,  and  adult  tick
stages (Figures 1  & 2).  After  hatching from the egg,  the larva must obtain a
blood meal to be able to develop into the next stage by moulting (Stanek et al.
2012). Development of one tick from an egg to an adult takes from two to six
years, depending on factors such as climate or availability of hosts (Piesman
& Gern 2004). As transmission of Borrelia occurs between hosts and ticks, at
least  the  nymph and  adult  stages  can  carry  and  spread  these  pathogens.  Of
adult  ticks,  only female ticks can spread Borrelia spirochaetes because they
need  a  blood  meal  before  laying  eggs  (Stanek  et  al.  2012).  Direct
transmission of Borrelia among hosts or vectors does not occur (Kurtenbach
et  al.  2006).  Transovarial  transmission  of  spirochaetes  in Ixodes ticks  is
reported  to  occur  only  with B. miyamotoi,  which  is  more  closely  related  to
the relapsing fever -group of Borrelia (Rollend et al. 2013).
Figure 1 Different developmental stages of Ixodes ricinus ticks with a scale bar. Larva has
only six legs whereas other developmental stages of tick have eight legs.
In Norway and Sweden, 99% of ticks are reported to be I. ricinus,  but in
Finland I. persulcatus has  also  been  reported  (Jääskeläinen  et  al.  2006;
Jaenson et  al.  2012;  Hvidsten et  al.  2013).  Mosquitos from different genera
and even horseflies can carry Borrelia spirochetes, but the documentation of
actual  infections  caused  by  mosquitos  and  horseflies  is  scarce  (Doby  et  al.
1987;  Magnarelli  &  Anderson  1988;  Luger  1990;  Nejedla  et  al.  2009).  The
mean prevalence of Borrelia burgdorferi sensu  lato  in  ticks  is  8.4%  in I.
ricinus and 12.5% in I. persulcatus in Russia (Gray et al. 2002) and 13.7% in
I. ricinus and 29.0% in I. persulcatus in Europe (Korenberg et al. 2002;
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Rauter  &  Hartung  2005).  In  a  recent  report  from  Sweden,  the  mean
prevalence was 26% (from 25% in nymphs up to 36% in adult  female ticks)
and  prevalence  varied  (from  11%  in  Northern  Sweden  up  to  31%  in  South
Central Sweden) between different areas of Sweden and Åland islands (part
of  Finland,  prevalence  23%)  (Wilhelmsson  et  al.  2013).  In  two  regional
studies in Finland, the proportion of ticks infected with Borrelia ranged from
19% to 55% in recreational areas of Helsinki and from 0 to 11.6% in parks of
Turku  and  rural  islands  of  the  Turku  archipelago  (Junttila  et  al.  1999;
Mäkinen et al. 2003).
Different animal species are known to carry Borrelia in nature (Figure 2)
(Piesman & Gern 2004; Franke et al. 2013). Birds and different small rodent
species  such  as  mice  are  common hosts  for  ticks  and  are  natural  reservoirs
for Borrelia (Piesman  &  Gern  2004).  Other  animals  such  as  deer,  foxes,
hedgehogs, badgers, rabbits, racoons and opossums may serve as carriers. In
some  cases,  different  lizard  species  can  also  carry Borrelia (Franke et al
2013).
How do Borrelia spirochaetes  survive  in  ticks?  During  the  blood  meal,
Borrelia spirochaetes  migrate  from  the  host  dermis  into  the  tick  gut  and
further into the gut lumen. The Borrelia spirochaetes must first adapt to the
change  in  the  temperature  and  then  must  stay  alive  inside  the  tick  (Pal  &
Fikrig 2003; Cabello et  al.  2007; Hovius et  al.  2007).  In ticks, Borrelia up-
regulate the expression of  outer surface proteins A and B (OspA and OspB)
among others (Yang et  al.  2004; Neelakanta et  al.  2007).  In the tick lumen
Borrelia are  attached  to  a  receptor  of  OspA  which  enables  them  to  avoid
elimination (Pal et al. 2004). After feeding for a few days (from three days for
larvae  and  up  to  seven  days  for  adult  female  ticks),  engorged  ticks  drop  off
and  find  their  way  to  the  soil  surface  where  it  is  more  humid  (Figure  3,
presenting both an unfed and engorged tick). Ixodes sp.  ticks  survive  in
temperatures between -10 and +35°C and tolerate extreme conditions for
only short time periods (Estrada-Pena et al. 2012). When the larva or nymph
hatches  or  the  adult  female  tick  prepares  to  lay  eggs,  they  must  come  into
contact with host species to be able to feed again.
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Figure 2 Circulation of Borrelia sp. presented here with Ixodes ricinus tick as a vector. The
duration of a full life cycle of Ixodes sp. tick is 2 years in optimal conditions
(Piesman & Gern 2004). A larva hatches from an egg during the spring, feeds
during the summer and is dormant during the winter. During the spring of the
second year, the larva develops into a nymph which develops further to an adult tick
during the summer. Adult ticks mate and the female tick lays eggs before winter.
Small rodents and birds can serve as reservoir animals for Borrelia; the orange
cross indicates non-reservoir host animals. In Europe, birds usually carry Borrelia
garinii and B. burgdorferi sensu stricto, whereas small rodents more often carry B.
afzelii and B. burgdorferi (Stanek et al. 2012). In the United States, B. burgdroferi
sensu stricto causes Lyme borreliosis (LB). At least nymphs and adult female ticks
can feed on humans and cause LB (Stanek et al 2012). Red arrows with
spirochaetes inside indicate the transmission of Borrelia; humans are only
accidental hosts.
After the ticks drop off, Borrelia spirochaetes have to find alternative
carbon sources  to  replace  the  glucose  (originating  from blood)  required  for
glycolysis and biosynthesis of phospholipids. The expression of borrelial
genes of the glp operon, which encodes proteins used in the uptake and
utilization  of  glycerol,  is  up-regulated  in  ticks  (He  et  al.  2011;  Pappas  et  al.
2011). It is poorly understood what kind of metabolic state enables Borrelia
to survive for long periods of nutrient deprivation in unfed nymphs (Pal and
Fikrig 2010). Protein La7 of Borrelia has been shown to be expressed mostly
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in ticks and down-regulated rapidly in mammalian infection. It has also been
shown  to  be  required  for  the  persistence  of Borrelia in non-mammalian
hosts (Yang et  al.  2013).  La7 (BB0365) is  an inner membrane protein of  22
kDa,  but  it  can  form  protein  complexes  with  outer  membrane  proteins  of
Borrelia sp.  and  is  able  to  interact  with  outer  membrane  proteins  such  as
OspA (von Lackum et al. 2007; Yang et al. 2011; Yang et al. 2013).
Figure 3 Ixodes sp. tick unfed (left) and engorged one (center and right) after feeding on a
domestic cat in Finland. The length of the unfed tick is approximately 2-3 mm while
the engorged tick is approximately 1 cm. On the left and center panels the back of
the tick is visible and on the right panel the underside of the tick is visible. Photos
Heidi Sillanpää.
While the Borrelia sp. infected tick feeds on a host and engorges, Borrelia
spirochaetes start their journey from the tick gut to the new host.
Spirochaetes  start  to  multiply  rapidly  in  the  lumen of  the  tick  gut  and  they
make a transition to motile organisms again while reaching the basolateral
surface  of  the  epithelium  (Dunham-Ems  et  al.  2009;  Radolf  et  al.  2012).
Earlier studies reported that spirochaetes down-regulate OspA and OspB and
up-regulate  OspC  (outer  surface  protein  C)  expression  instead,  which  is
needed  when  invading  tick’s  salivary  glands  and  infecting  vertebrate  hosts
(Munderloh & Kurtti 2005). The down-regulation of OspA does not happen
rapidly (if  happening at  all)  at  the time spirochaetes make the transition to
the motile state again (Schwan & Piesman 2000; Mulay et al. 2009). Some of
the Borrelia are  able  to  travel  through  the  epithelium  of  the  gut  to  the
hemocoel (fluid-filled space surrounding the tick midgut and containing the
salivary glands) and towards tick’s salivary glands (Kung et al. 2013; Sultan
et al. 2013). Recently, it has been shown that the borrelial surface membrane
protein BBE31 interacts  with the tick epithelial  cell  secreted protein TRE31,
which may help the spirochaetes penetrate the midgut (Zhang et al. 2011).
Along with tick saliva, spirochaetes reach the host dermis and encounter
the host immune defence (Schuijt et al. 2011). Transmission of Borrelia from
tick  to  human  or  other  hosts  takes  approximately  24  hours  (Stanek  et  al.
2012). Time needed for transmission varies between Borrelia species and
different hosts. Transmission to humans occurs mostly from late May to late
September;  a  time  period  when  nymphs  are  active  and  recreational  use  of
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tick  habitats  increases  by  people  (Smith  et  al.  2011;  Stanek  et  al.  2012).  In
Finland, most of the LB cases are found during the autumn, from August to
November (The National Institute of Health and Welfare, Finland; Infectious
Diseases in Finland database http://www.thl.fi/ttr/gen/rpt/tilastot.html (in
Finnish), accessed 26.6.2014).
Climate  change  and  global  warming  have  resulted  in  changes  in  the
distribution  of  tick  species.  They  are  found  both  in  higher  latitudes  and  in
higher  altitudes  than  earlier  (Herrmann  &  Gern  2013).  Warming  of  the
climate  leads  to  longer  vegetation  periods  and  shifts  the  distribution  of
Ixodes ricinus ticks northwards and thus increases the risk of LB (Jaenson &
Lindgren 2011).
In  addition  to  LB,  several  other  diseases  are  transmitted  by Ixodes sp.
ticks as well as other tick vectors all over the world (Ivanova et al. 2013). For
example, ehrlichiosis, tularemia, babesiosis, anaplasmosis, Rocky Mountain
spotted fever, tick-borne encephalitis, Colorado tick fever, and tick-borne
relapsing fever are tick transmitted diseases in NorthAmerica, while
tularemia and tick-borne encephalitis are found in Finland (Seppänen 2011;
Shah  &  Sood  2013).  In  recent  studies,  one  new  bacterial  species  candidate
Neoehrlichia mikurensis (family Anaplasmataceae)  has  been  shown  to  be
spread via Ixodes ticks and its distribution and pathogenesis are studied also
in Europe (Kawahara et al. 2004; Hornok et al. 2013; Andersson et al. 2014;
Derdakova et al. 2014; Glatz et al. 2014; Grankvist et al. 2014; Palomar et al.
2014; Welc-Faleciak et al. 2014).
2.3 TAXONOMY OF THE GENUS BORRELIA
Taxonomically, the genus Borrelia belongs to the phylum Spirochaetes, class
Spirochaetia, order Spirochaetales, and family Spirochaetaceae. The other
three genera in the Spirochaetaceae family are Treponema, Spirochaeta, and
Cristisprira (Wang and Schwartz 2011). Development of laboratory methods
used  in  taxonomic  and  phylogenetic  studies  from  whole  DNA-DNA
hybridization (WDDH) to multi-locus sequence analysis (MLSA) has enabled
faster identification of new Borrelia species  (Franke  et  al.  2013). Borrelia
burgdorferi sensu lato (the Lyme borreliosis group of spirochaetes) is at the
moment a group of 20 spirochaetal bacteria from the genus Borrelia (Figure
4) (Margos et al. 2011; Ivanova et al. 2013). Several strains are still waiting to
be  phylogenetically  characterized  (Franke  et  al.  2013).  The  species  in  the
Lyme borreliosis group can be divided into pathogenic species (causing LB),
non-pathogenic species and species of uncertain pathogenicity (Margos et al.
2011). Five Borrelia species  are  known  to  cause  LB  in  Europe  and  these
species are B. burgdorferi sensu stricto (referred often as B. burgdorferi), B.
garinii, B. afzelii, B. spielmanii, and B. bavariensis (Stanek  et  al.  2012).
Three other species (B. valaisiana, B. bissettii, B. lusitaniae) are occasionally
detected in patients (Hubalek & Halouzka 1997; Collares-Pereira et al. 2004;
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Rudenko et al. 2009; Stanek & Reiter 2011). The rest of the species are either
non-pathogenic or of unknown pathogenicity. The Lyme borreliosis group of
spirochaetes differs phylogenetically based on 16S rRNA sequences from
relapsing fever causing Borrelia species and from the reptile-associated
group of Borrelia species (Wang and Schwartz 2011).
Figure 4 Borrelia species can be categorized into three different groups: reptile associated
group, Lyme disease group and relapsing fever group. The distribution of 20 Lyme
borreliosis (LB) group of Borrelia spirochaetes on four continents is shown. Species
known to cause LB in humans are marked with an asterisk. Novel, unnamed strains
(or possible species) are not shown in this figure. Adapted from Margos et al. 2011,
Stanek & Reiter 2011, Ivanova et al 2013, Platonov et al 2011, Cutler 2012, and
Assous et Wilamowski 2009 (Assous & Wilamowski 2009; Margos et al. 2011;
Platonov et al. 2011; Stanek & Reiter 2011; Cutler et al. 2012; Ivanova et al. 2013).
According to the List of Prokaryotic names with Standing in Nomenclature
(http://www.bacterio.net/index.html, accessed 26.6.2014) there are still seven
Borrelia species listed (B. tillae, B.mazzottii, B. dugesii, B. brasiliensis, B.
venezuelensis, B. graingeri, and B. harveyi) which are not presented in this figure
due to lack of publications after the first articles presenting the discovery of these
species several decades ago.
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2.4 GEOGRAPHICAL DISTRIBUTION OF LYME
BORRELIOSIS
LB Borrelia species are distributed mostly in the northern hemisphere
(Franke et al. 2013). The distribution of Borrelia species in Europe is shown
in Figure 5. In a recent study, the prevalence of different Borrelia species was
analysed from ticks in the Finnish Åland islands (Wilhelmsson et  al.  2013).
Percentages of Borrelia species in ticks were: 48% B. afzelii, 24% B. garinii,
8% B. valaisiana, 3% B. spielmanii, 2% B. burgdorferi sensu stricto, and 1%
B. miyamotoi.  1% of  ticks  had  a  mixed  infection  of  several Borrelia species
and 13% of ticks had an untypeable infection.
Figure 5 Simplified outlook of the distribution of Borrelia species in ticks in Europe (adapted
from Franke et al. 2013). B. burgdorferi sensu lato species (species causing Lyme
borreliosis in humans) are B. afzelii (afz), B. garinii (gar), B. burgdorferi sensu
stricto (ss), B. lusitaniae (lus), B. spielmanii (spi), B. bavariensis (bav) and B.
valaisiana (val). Other abbreviations in the map indicate occurrence of B. bissettii
(bis) and B. finlandensis (fin). B. finlandensis was isolated from Ixodes ricinus ticks
and its pathogenicity to humans is unknown.
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There are some studies of LB Borrelia species in ticks in Northern Africa
(Zhioua  et  al.  1999;  Sarih  et  al.  2003;  Younsi  et  al.  2005).  A  new Borrelia
species, B. chilensis, was  recently  reported  in  South  America0  and B.
burgdorferi sensu  lato  has  been  shown  to  infect Ixodes ticks  in  Uruguay
(Barbieri  et  al.  2013;  Ivanova  et  al.  2013).  Lyme disease-like  syndrome has
also been reported in South America,  especially  from the Amazon region in
Brazil, although the spirochaetal agent remains unidentified (Mantovani et
al. 2007; Talhari et al. 2010). To date, Australia is the only continent besides
Antarctica without solid evidence for the existence of Lyme disease
spirochaetes  (Franke  et  al.  2013).  There  is  only  one  report  of  a  culture-
positive  Lyme  borreliosis  in  Australia,  one  report  of  four  patients  with  EM
skin biopsy tested positive for Lyme borreliosis, and one report of 28 patients
tested positive to Lyme borreliosis with IFA, western blot or PCR or all three
methods (Hudson et al. 1998; Mayne 2011; Mayne 2012).
In recent years, the incidence of Lyme borreliosis in Europe has been
increasing  and  the  ranges  of  reported  cases  is  from  69  per  100  000
population in Sweden to 111 per 100 00o population in Germany (Stanek et
al.  2012).  In  the  United  States,  the  annual  count  of  confirmed  LB  cases  is
around 30 000, but CDC has estimated that it may be even 300 000 (Embers
&  Narasimhan  2013;  Kuehn  2013).  The  incidence  of  LB  in  Finland  was
reported to be 31 per 100 000 population in 2013 (The National Institute of
Health and Welfare, Finland; Infectious Diseases in Finland -database
http://www.thl.fi/ttr/gen/rpt/tilastot.html (in Finnish), accessed 26.6.2014).
In  the  Åland  islands  (part  of  Finland),  it  was  1621  per  100 000 population;
the  incidence  varies  significantly  by  region  as  shown  in  Figure  6.  The
Infectious Diseases in Finland -database includes LB patients who have
tested positive for Borrelia, but not those whose treatment is based solely on
clinical diagnosis of EM. Laboratory test results do not separate patients with
acute  disease  from  those  with  antibodies  from  past  infection  (Wilske  et  al.
2007).  The  actual  amount  of  LB  patients  yearly  may  be  higher  than  cases
reported into the Infectious Diseases in Finland -database.
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Figure 6 The incidence of Lyme borreliosis cases per 100 000 population in 2013 according
to the hospital districts in Finland. The incidence is calculated from the cases
reported by the hospital districts to the Infectious Diseases database of the Finnish
National Institute of Health and Welfare in year 2013. Incidence values with an
asterisk are from the year 2012 due to lack of data from the year 2013. Figure
includes material from the general map raster 1:4 500 000 (2012) of National Land
Survey of Finland.
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2.6 CELL BIOLOGY OF BORRELIA
Members of Borrelia burgdorferi sensu  lato  share  the  common  structural
features of spirochaetes. They are Gram-negative bacteria and
microaerophilic. They are motile, spiral cells with a length of 20-30 µm and
diameter of  0.2-0.3 µm (Barbour & Hayes 1986; Wang and Schwartz 2011).
The cell envelope consists of the inner cell membrane, the peptidoglycan
layer,  and  the  lipoprotein-based  outer  membrane  (Figure  7)  (Radolf  et  al.
2012). Of the antimicrobial agents, Borrelia spirochaetes  are  susceptible  to
penicillins, second- and third-generation cephalosporins, tetracyclines,
macrolides and glycolipids, but they are resistant to aminoglycosides,
trimethoprim, rifampicin, and quinolones (Preac-Mursic et al. 1986;
Wormser et al. 2006).
The  outer  cell  membrane  contains  a  low density  of  membrane-spanning
proteins  (e.g.  P13,  P66,  BesC,  BamA,  Lmp1,  and  BB0405)  and  lacks  the
lipopolysaccharides  (LPS)  typical  of  other  Gram-negative  bacteria  (Hefty  et
al. 2002b; Kung et al. 2013). Instead, there are membrane-anchored
glycolipids  of  low molecular  weight  and  numerous  triacylated  proteins  (e.g.
OspA, OspB, OspC, OspD, OspE, OspF, DbpA, DbpB, CspA, BptA, VlsE,
BbCRASP, BBK32, and BBA64) (Hefty et al. 2002b). Some of the glycolipids
are  expressed  also  on  the  periplasmic  side  of  the  outer  membrane  and
Borrelia spirochaetes  are  able  to  change  the  location  of  these  glycolipids
between outer membrane surface and periplasmic side at different points of
infection (Cox et al. 1996; Hefty et al. 2002b).
The  outer  cell  membrane  surrounds  a  protoplasmic  cylinder  complex
(Figure  7)  (Radolf  et  al.  2012).  The  flagella  are  located  in  the  periplasmic
space  where  they  are  attached  to  the  both  termini  of  protoplasmic  cylinder
(7-11 copies in both ends) (Wang and Schwartz 2011). The flagella of Borrelia
spirochaetes  are  made  of  four  components:  hook,  filament,  neck  and  basal
disk  and  resemble  the  flagella  of  gram-positive  bacteria  (Barbour  &  Hayes
1986).  The  flagellar  filaments  form  flat  ribbons  that  coil  along  the
protoplasmic cylinder complex between the peptidoglycan layer and the
outer  membrane  (Figures  7  and  8)  (Charon  et  al.  2009).  Even  though
Borrelia species have been classified as Gram-negative, some of their
features  (e.g.  two  lipid  bilayer,  fluid  outer  cell  membrane,  and  no  LPS)
separate them from other Gram-negative bacteria (such as Escherichia coli)
underlining their unique status among bacteria (Barbour et al. 1986;
Bergtröm et al. 2010). It is not known if Borrelia canproduce toxins (Stanek
et al. 2012).
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Figure 7 The cell envelope of Borrelia spirochetes (adapted from Radolf et al. 2012 and
Kenedy et al. 2012). The Borrelial cell envelope has an outer membrane containing
a high density of outer-surface lipoproteins (OspA, OspC, VlsE, and DbpB) and a
low density of outer membrane spanning proteins (e.g. P13). Some of the outer-
surface proteins have functions in immune evasion (e.g. BbCRASP). There are
some lipoproteins anchored to the inner side of the outer membrane (e.g. Lp6.6).
Flagella are situated in the periplasmic space. The cell envelope also has a
peptidoglycan layer and an inner membrane containing a high density of integral
membrane proteins (e.g. GlpF). Peptidoglycan consists of N-acetyl glucosamine
(green) and N-acetyl muramic acid (orange) connected with two tetrapeptide chains
cross-linked with peptide (black symbols connecting two N-acetyl muramic acids in
Figure). BbCRASP, B. burgdorferi complement regulator-acquiring surface protein;
GlpF, glycerol uptake facilitator in glycerol transport and metabolism; P13, integral
membrane porin protein
The  relatively  small  genome  is  1.5  megabases  and  consists  of  one  linear
chromosome  and  several  linear  and  circular  plasmids  (21  plasmids  in B.
burgdorferi ss  B31M1),  which  is  unique  among  prokaryotes  (Fraser  et  al.
1997; Casjens et al. 2000). Linear plasmids also have a hairpin-like telomere
structure  at  both  ends.  Telomeres  are  very  rarely  seen  in  bacteria;  they  are
found  in  some  animal  viruses  and  are  common  in  eukaryotes  (Barbour  &
Garon  1987;  Casjens  1999).  The  G+C  content  is  approximately  30  mol%
(Wang  and  Schwartz  2011).  The  genomes  of  at  least  six  Lyme  disease
Borrelia species have been completely determined (Fraser et al. 1997;
Glockner  et  al.  2004;  Casjens  et  al.  2011;  Schutzer  et  al.  2012).  The
proportion  of  plasmid  DNA varies  between Borrelia species: approximately
40% in B. burgdorferi ss B31M1, 29% in B. garinii Bpi and 36% in B. afzelii
Pko (Wang and Schwartz 2011).  The chromosome encodes the basic  house-
keeping genes while the plasmids contain genes for specialized functions
related  to  adaptation  (Pal  &  Fikrig  2003).  Most  of  the  genes  encoding
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enzymes required for the synthesis of most amino acids, fatty acids, enzyme
cofactors and nucleotides are missing from B. burgdorferi.  93%  of  the
chromosome  and  71%  of  plasmids  contain  coding  sequence  (Fraser  et  al.
1997). A significantly high proportion of genes encode lipoproteins (4.9% in
the chromosome, 14.5% in plasmids), and interestingly, 38.9% of the genes of
B. burgdorferi B31M1 have an unknown function or they lack homologues in
other bacterial species. In addition, there is evidence of numerous and
potentially recent DNA rearrangements among plasmid genes (Fraser et al.
1997;  Casjens  et  al.  2000).  Of  the  genes  encoded  in  plasmids,  most  are
unique to Borrelia (Fraser et al. 1997).
Figure 8 Longitudal and cross-sectional structure graphs of Borrelia burgdorferi spirochaete
(adapted from Charon et al. 2012). Periplasmic flagella overlap in the middle. In
longitudal structure graphs, only one flagellum at both ends of a spirochete is
shown for the sake of simplicity. Length of one spirochaete is 20-30 µm and
diameter 0.2-0.3 µm (Barbour & Hayes 1986).
Regulation of gene expression (global gene regulation) in Borrelia is  a
complex  combination  of  signalling  systems,  enhancers  and  regulators
(Samuels  2011;  Groshong  &  Blevins  2014).  Alternative  RNA  polymerase  σ-
factors  N  and  S  (RpoN,  RpoS)  together  with  response  regulatory  proteins  1
and  2  (Rrp1,  Rrp2)  and  histidine  kinases  1  and  2  (Hk1,  Hk2)  form  a
regulatory pathway which controls the gene expression of numerous genes
during  the  enzootic  cycle  of  LB Borrelia and  is  essential  in  spirochaetal
transmission  and  mammalian  infection  (Hubner  et  al.  2001;  Yang  et  al.
2003; Yang et al. 2003; Caimano et al. 2007; Boardman et al. 2008; Ouyang
et  al.  2008).  This  pathway  controls  for  example  expression  of  DbpA  and
OspC (Hubner et al. 2001).
In vitro, Borrelia spirochetes can be grown in Barbour-Stoenner-Kelly II
(BSK  II)  medium  or  its  derivate  BSK-H,  or  in  MPK  (modified  Kelly’s
medium) (Barbour 1984; Preac-Mursic et al. 1986; Pollack et al. 1993).
Growth of the Borrelia depends greatly on nutrients available in the growth
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medium  or  in  ticks  gut  or  host  (Wang  and  Schwartz  2011).  Changes  in  the
temperature and pH (among others) can be used to mimic the environments
which spirochetes encounter either in unfed tick (lower temperature with
higher pH) or fed tick or host (mammal) (higher temperature with lower pH)
(Yang et  al.  2000).  Many compounds,  such as rabbit  serum used in growth
medium, can act as chemoattractants to Borrelia (Shi et al. 1998; Bakker et
al. 2007).
2.6.1 VLSE AND DECORIN BINDING PROTEINS OF BORRELIA
The high density of lipoproteins anchored to the outer membrane of Borrelia
sp.  is  one  of  the  features  that  make Borrelia spirochaetes unique among
prokaryotes (Radolf et al. 2012). The ability of Borrelia to  change  the
expression of the outer membrane proteins (omps) even at different stages of
infection impacts the pathogenicity of Borrelia (Cox et  al.  1996; Hefty et  al.
2002b; Stanek et al. 2012). Characterisation of omps has been a major focus
in research, including development of diagnostic methods and vaccines
(Radolf  et  al.  2012).  Studies  have  revealed  a  number  of  specific  surface
proteins that Borrelia uses to promote pathogen-host interactions in ticks,
mammals, or both (Groshong & Blevins 2014).
The variable major protein system (Vmp) is a complex mechanism for the
variation of surface exposed proteins, first described in relapsing-fever
causing Borrelia hermsii (Barbour  1993).  In  LB Borrelia this  system  is
named vls (vmp-like sequence) and the vls gene encodes a 35 kDa outer
surface lipoprotein VlsE (Zhang et al. 1997). A vls expression site (vlsE) and
15 additional silent vls gene cassettes are found in the linear plasmid lp28-1
near its telomere site (Figure 9) (Zhang et al. 1997). All the vls cassettes have
the same 17 bp long direct repeat section at both ends of each cassette. These
direct repeats facilitate the recombination between the expressed and silent
vls sequences  (Zhang  et  al.  1997;  Zhang  &  Norris  1998a).  One vls cassette
contains six variable regions and six highly conserved, invariable regions
(Zhang et al. 1997). Structural analyses of the VlsE protein have shown that
variable  regions  are  hidden  under  the  surface  of  the  VlsE  protein  and
protected that  way from the antibody recognition (Liang et  al.  1999a;  Liang
et al. 2000; Eicken et al. 2002).
Recombination of the vls gene  helps  the Borrelia spirochaetes avoid
recognition by the host immune system. This recombination takes place only
when Borrelia are  subjected  to  immune  pressure  (Zhang  &  Norris  1998b;
Indest  et  al.  2001;  Liang  et  al.  2004b;  Coutte  et  al.  2009).  Point  mutations
can  also  accumulate  in  the vls expression cassette, facilitating immune
evasion  (Sung  et  al.  2001;  Coutte  et  al.  2009).  The  precise  mechanisms  by
which the vlsE antigenic variation system promotes infection is unknown, as
well  as  which  mammalian  signals  activate  the  VlsE  expression  and  its
antigenic variation with vls cassettes (Groshong & Blevins 2014).
Interestingly,  analyses  of  the  tertiary  structure  of  the  VlsE  monomer  and
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OspC  dimer  have  revealed  that  they  are  similar  in  shape  and  size,  having
surface-exposed loops of variable regions even though OspC and VlsE are not
homologous  in  DNA  sequence  (Eicken  et  al.  2001;  Kumaran  et  al.  2001;
Eicken  et  al.  2002).  OspC  and  VlsE  might  have  a  common  function  in
protecting the Borrelia in particular host environments or alternatively
stabilizing its structure (Tilly et al. 2013).
Figure 9 VlsE protein expression site in linear plasmid 28-1 (a), structure of VlsE gene (b)
and one of the vls cassettes (c) illustrated after Zhang et al 1997. DR, direct repeat;
IR, invariable region; VR, variable region.
Borrelia spirochaetes have several proteins for adhesion to host epithelial
surfaces (Coburn et al. 2013; Brissette & Gaultney 2014). Proteins binding to
mammalian extracellular matrices include BmpA, BBK32, CRASP-1, CRASP-
2,  DbpA,  DbpB,  RevA,  RevB  and  ErpX  (Coburn  et  al.  2013;  Brissette  &
Gaultney  2014).  BBK32  is  a  protein  which  binds  to  fibronectin  and
glycosaminoglycan (GAG), BpmA and ErpX bind laminin, RevA and RevB
bind fibrinogen, DbpA and DbpB proteins (decorin binding protein A and B)
bind to decorin and dermatan sulfate glycosaminoglycan, and CRASP-1 and
CRASP-2 bind fibronectin, laminin, and collagen but also complement
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regulatory  proteins  (Guo  et  al.  1995;  Guo  et  al.  1998;  Probert  &  Johnson
1998;  Hartmann  et  al.  2006;  Brissette  et  al.  2009a;  Brissette  et  al.  2009b;
Brissette et al. 2010; Hallstrom et al. 2010).
Decorin  is  one  of  the  small  leucine-rich  proteoglycans  found  in  the
extracellular matrix.  It  consists  of  a  protein core with 12 leucine-rich repeat
domains  and  one  tissue-specific  chondroitin  or  dermatan  sulphate
glycosaminoglycan  side  chain  covalently  bound  to  its  amino  terminal  end
(Guo et al. 1995; Schaefer & Iozzo 2008). High concentrations of decorin are
found in joints, skin and endothelium (Järveläinen et al. 1991). Decorin is
expressed all  over the body,  also in the central  nervous system (Järveläinen
et  al.  1991;  Hanemann  et  al.  1993;  Kallmann  et  al.  2002).  Besides  being  a
structural  part  of  the  extracellular  matrix,  decorin  (amongst  other  small
leucine-rich proteoglycans) also acts as a signalling molecule when present in
soluble form and binds to some of the receptor tyrosine kinases and toll-like
receptors 2 and 4, resulting in the regulation of several cellular processes
(Frey et al. 2013).
The size of  DbpA is  about 20 kDa and that  of  DbpB 19 kDa.  A two-gene
operon  encoding  these  two  proteins  is  found  in  the  linear  plasmid  lp-54
(genes bba24 and bba25) (Fraser et al. 1997; Hagman et al. 1998; Roberts et
al. 1998). Amino acid sequences of both DbpA and DbpB have been shown to
vary between different Borrelia species and even between different strains of
one Borrelia species.  Similarity  of  sequences  from  different  species  is
between  58.3%  and  100%  for  DbpA,  with  the  highest  similarity  between
strains of one species of B. burgdorferi ss (Roberts et al. 1998). Similarity of
DbpB sequences  in B. burgdorferi ss  strains  is  over  96%,  but  from 62% to
67% between three different B. burgdorferi sensu lato species (Roberts et al.
1998;  Heikkilä  et  al.  2002a).  These  decorin  binding  proteins  are  not
expressed in ticks, but instead, the up-regulation of the expression starts
when ticks are feeding on a host.   In mammals,  the expression continues at
least for several weeks (Hagman et al. 2000; Hodzic et al. 2002; Hodzic et al.
2003).
Antibodies  towards  DbpA  and  DbpB  are  detectable  throughout  the
infection; it is likely that these proteins are expressed in mammals constantly
(Hagman et  al.  1998;  Embers  et  al.  2012).  Binding  properties  of  DbpA and
DbpB have been shown to differ. While both Dbps bind dermatan sulphate,
the binding of  DbpB can be inhibited with chondroitin-6-sulfate (Fischer et
al.  2003).  DbpA  has  been  shown  to  have  greater  affinity  to  decorin  than
DbpB and also the allelic variation makes differences in the affinity of DbpA
(Guo et al. 1998; Benoit et al. 2011). The allelic variation of DbpB has thus far
only been studied between three Borrelia species (Heikkilä et al. 2002a). The
binding properties of recombinant Dbps to decorin varies such that DbpA of
B. garinii and  DbpB  of B. garinii and B. burgdorferi ss  show  stronger
adherence to decorin compared to DbpA of B. burgdorferi and B. afzelii and
DbpB of B. afzelii (Salo  et  al.  2011).  Genetic  variations  of  DbpA  (allelic
variation)  have  effects  on  the  binding  properties  of  LB Borrelia species
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(Benoit  et  al.  2011).  Decorin  binding  properties  have  been  shown  to  be
important for the dissemination of Borrelia (Liang et al. 2004a).  Both DbpA
and DbpB from both B. garinii and B. burgdorferi have  been  shown  to
support the adherence of Borrelia to decorin and decorin-expressing cells in
vitro (Salo et al. 2011).
2.6.2 IMMUNE EVASION OF BORRELIA SPIROCHETES
Motility  and  chemotaxis  seem  to  be  important  for  the  survival  of Borrelia
spirochaetes  both  in  ticks  and  hosts  (Sultan  et  al.  2013).  It  has  also  been
shown that Borrelia might  be  able  to  penetrate  through  epithelial  cells
(Comstock & Thomas 1989). The swimming speed of Borrelia spirochaetes in
liquid  is  4  µm/s  and  swimming  speed  has  been  shown to  increase  together
with  the  viscoelasticity  of  the  environment  (Kimsey  &  Spielman  1990;
Goldstein et al. 1994). Mutant strains of B. burgdorferi (periplasmic flagellar
motor mutant; chemotaxis-deficient mutant) have been shown to be
attenuated or unable to infect mice (Li et al. 2010; Sze et al. 2012). Borrelia
have methyl-accepting chemotaxis proteins that can bind molecules that are
either attractant or repellent for them (Xu et al. 2011). Chemotaxis response
regulator  (Che)  proteins  are  located  near  flagellar  motors  and  transmit  the
environmental signals to the motors by modulating the phosphorylation state
of the two-component system CheA-CheY of chemotaxis (Goldstein et al.
2010; Xu et al. 2011).
Changing the expression of surface proteins is one way to evade the host
immune system (Radolf et al. 2012). Borrelia spirochaetes are able to change
the  composition  of  at  least  one  surface  protein,  VlsE,  helping  them  escape
attack from the adaptive immune system of  the host  (Zhang et  al.  1997).  In
addition to the changes in the expression of lipoproteins, Borrelia can
change the cellular location of  the lipoproteins between the cell  surface and
periplasmic space and avoid contact with specific antibodies and clearance
from  the  host  (Hefty  et  al.  2002b;  Kenedy  et  al.  2012).  For  example,
expression  of  OspC  is  down-regulated  after  entering  a  mammalian  host
probably  due  to  development  of  specific  anti-OspC  antibodies,  while  other
proteins  like  DbpA  and  DbpB  are  up-regulated  (Liang  et  al.  2004b).  It  is
currently not clear what kind of protective pathways Borrelia are using
against oxidative stress caused by ticks or host animals (Groshong & Blevins
2014).
All  three  complement  activation  pathways  (the  classical,  lectin  and
alternative pathways) are activated in Lyme borreliosis (van Dam et al. 1997;
Kurtenbach et al. 2002; Schuijt et al. 2011). Some of the Borrelia species (B.
burgdorferi ss (moderately), B. afzelii, B. bavariensis and B. spielmanii) are
known to  be  serum resistant  in  humans,  whereas  at  least B. garinii and B.
lucitaniae are serum sensitive, although sensitivity varies between different
strains of one Borrelia species  (van  Dam  et  al.  1997;  Bhide  et  al.  2005;  de
Taeye  et  al.  2013). Borrelia spirochaetes evade complement pathways by
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three different ways: a) they recruit mammalian host complement regulators,
b)  exploit  tick  proteins,  and  c)  possess  factors  which  affect  the  host
complement system (de Taeye et al. 2013).
Borrelia isolates surviving in human serum express complement
regulator acquiring surface proteins (CRASPs or BbCRASPs) on their surface
(Kraiczy  et  al.  2004b;  Brooks  et  al.  2005;  Kenedy  &  Akins  2011).  CRASPs
bind  several  host  proteins  of  the  factor  H  family  (factor  H,  factor  H-like
protein  1,  factor  H-related  proteins  1,  2  and/or  5)  (Kraiczy  &  Stevenson
2013). There are five different CRASPs: CRASP-1 (encoded by cspA), CRASP-
2 (encoded by cspZ),  CRASP-3  (encoded  by erpP), CRASP-4 (encoded by
erpC), and CRASP-5 (encoded by erpA) (Stevenson et al. 1996; Casjens et al.
2000; Kraiczy et al. 2003; Kraiczy et al. 2004a; Kraiczy et al. 2004b;
Hartmann et al. 2006). CRASP-encoding sequences have been identified only
in the genus Borrelia (Kraiczy  &  Stevenson  2013).  In  addition, Borrelia
spirochaetes have a binding receptor for C4b-binding protein (C4bp) on their
surface (de Taeye et al. 2013).
Borrelia spirochaetes also avoid complement killing in mammals with the
help of tick proteins (Figure 10). While tick is feeding, it releases several
proteins in its saliva to eliminate pain and irritation at the site of feeding
(Ribeiro et al. 1985; Ribeiro 1987; Paesen et al. 1999; Valenzuela et al. 2002).
Salival  proteins  also  hamper  the  response  of  natural  killer  cells  and
production  of  antibodies  and  suppress  T-cell  proliferation  (Wikel  1999;
Gillespie  et  al.  2000;  Gillespie  et  al.  2001).  Tick  salivary  lectin  pathway
inhibitor -protein (TSLPI) prevents the binding of mannose-binding lectin to
its ligand (unknown) on Borrelia and also inhibits complement activation via
human L-ficolin (Schuijt et al. 2011). Borrelia also benefit from tick salivary
protein Salp20, which displaces properdin from the C3 convertase complex
leading to destabilized C3 convertase and inhibition of complement (Tyson et
al.  2007;  Tyson  et  al.  2008).  Tick  salivary  protein  Salp15  binds  to  outer
surface  protein  C  (OspC)  of Borrelia and protects Borrelia from both
antibody  and  complement  mediated  killing  (Ramamoorthi  et  al.  2005;
Hovius et al. 2008b; Schuijt et al. 2008). Salp15 also inhibits T-cell activation
and Borrelia-induced proinflammatory cytokine production by dendritic
cells and dendritic cell induced activation of T cells, and Salp15 also suppress
the production of interleukin-2 (IL-2) (Hovius et al. 2008a; Liu et al. 2014).
Some serum resistant Borrelia also possess at least one surface-expressed
CD59-like protein, facilitating avoidance of complement-mediated lysis
(Pausa  et  al.  2003). Borrelia also  binds  hosts  plasminogen  with  enolase  on
its  surface  to  facilitate  invasion,  and  OspC  may  be  one  of  the  plasminogen
receptorson the surface of Borrelia spirochaetes (Coleman et al. 1995; Floden
et al. 2011; Onder et al. 2012).
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Figure 10 Innate immune system responses towards Borrelia spirochaetes. Some responses
of adaptive immune system, such as antibodies, are also shown. While Ixodes sp.
tick is feeding, Borrelia spirochaetes are transferred into a new host along the flow
of tick saliva. Penetration of tick mouthparts (chelicerae and hypostome) into the
dermis cause local inflammation (Bockenstedt et al. 2014). Tick saliva contains
several proteins that impair wound healing, suppress coagulation of blood,
inflammation, and host immune defences (Ribeiro et al. 1985). Borrelia is
recognized by dendritic cells (DC), Langerhans cells (LC), and macrophages
(Rupprecht et al. 2008b; Mason et al. 2014). Dendritic cells and macrophages
phagocytose Borrelia and some antigen presenting cells recognize Borrelia
spirochaetes with specific receptors or antibodies bound to the surface of Borrelia.
Macrophages and dendritic cells release cytokines and chemokines in order to
recruit more cells to the site of infection (Strle et al. 2009; Mason et al. 2014).
Complement is also activated (all three pathways) (van Dam et al. 1997;
Kurtenbach et al. 2002; Schuijt et al. 2011). Borrelia spirochaetes can avoid
immune system attack in various ways. They can swim away faster than dendritic
cells and macrophages can follow, or they can bind proteins from tick saliva or from
the host on their surface to avoid recognition (Rupprecht et al. 2008b; Schuijt et al.
2011; Sultan et al. 2013). Proteins from tick saliva also help Borrelia avoid the
immune system by imparing maturation and differentiation of dendritic cells
(Skallova et al. 2008). Adapted from Mason et al. 2014.
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Borrelia benefits  from  tick  saliva  proteins  which  also  influence  other
parts of the immune system besides complement. Dendritic cells survey our
body  for  possible  pathogens  and  if  one  is  recognized,  they  start  producing
cytokines which affect innate and adaptive immune systems (Banchereau &
Steinman 1998). Dendritic cells and macrophages are among the first cells of
our immune system which encounter Borrelia in  the  skin  (Mason  et  al.
2014). Both dendritic cells and macrophages have pattern recognition
receptors (Toll-like receptors and NOD-like receptors among others) on their
surface. There receptors may be employed in the recognition of lipoproteins
from Borrelia spirochaetes,  leading  to  phagocytosis  of  spirochaetes  and
activation  of  a  molecular  signalling  cascade,  resulting  in  release  of  several
cytokines and chemokines which attract other inflammatory cells to the tick
bite site (Radolf et al. 2012; Mason et al. 2014). Tick saliva has been shown to
have negative effects on the maturation and differentiation of dendritic cells
(Skallova  et  al.  2008).  Proteins  of  tick  saliva  interfere  with  the  signalling
pathways of dendritic cell receptors, leading to decreased production of
cytokine TNF-α and attenuated response to Borrelia spirochaetes
(Lieskovska & Kopecky 2012).
2.7 CLINICAL SYMPTOMS OF LYME BORRELIOSIS
Manifestations  of  LB  are  traditionally  divided  into  three  categories:  early
(localized) disease, early disseminated disease and late (persistent) disease
(Brouqui  et  al.  2004).  The  first  manifestations  usually  appear  on  the  skin
around  the  tick  bite  site  in  a  form  of  red  rash  (sometimes  bull’s-eye  like),
erythema migrans (Steere 2001). Dissemination of Borrelia from  skin  to
blood  and  via  blood  circulation  all  over  the  body  is  strain  dependent  (van
Dam  et  al.  1993;  Wormser  et  al.  2008;  Brisson  et  al.  2011).  Symptoms  of
disseminated LB vary and there are several different kinds of manifestations
in joints,  heart,  skin and central  nervous system (Steere 2001).  Most of  the
tissue  damage  seems  to  originate  from  inflammatory  response  of  host
(Stanek et al. 2013).
Different Borrelia species may be associated with different symptoms. B.
afzelii is linked to chronic skin manifestations, B. garinii and B. bavariensis
to neuroborreliosis, but B. valaisiana very rarely associated with human
disease (Canica et al. 1993; Rijpkema et al. 1997; Wang et al. 1999a; Ornstein
et  al.  2001;  Ruzic-Sabljic  et  al.  2001;  Tijsse-Klasen  et  al.  2013).  It  has  also
been reported that multi-infection with more than one B. burgdorferi sensu
lato species can lead to ambiguous clinical outcome (Franke et al. 2013). Due
to the different distribution of Borrelia species (see Figure 5 on page 20), the
symptoms of  the disease can vary,  for  example between North America and
Europe (Steere 2001). In endemic areas, it is possible to become re-infected
with LB spirochaetes and have manifestations of LB again (Golde et al. 1998;
Nadelman et al. 2012; Jares et al. 2014).
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2.7.1 ERYTHEMA MIGRANS
Erythema migrans (EM), earlier referred as erythema chronicum migrans, is
a slowly expanding skin lesion which usually appears around the tick bite as
a first  sign of  Lyme borreliosis  (Steere et  al.  1983; Steere 2001).  EM is  also
the most common manifestation of LB (Strle & Stanek 2009). The rash is red
or  bluish-red  and  over  5  cm  in  diameter  either  with  or  without  central
clearing (Figure 11) (Stanek et al. 2012). The diameter of the rash grows and
EM usually  occurs after  several  days or weeks,  even up to 30 days after  the
tick bite, as spirochaetes first multiply near the tick bite site and then migrate
centrifugally (Stanek et al. 2011; Halperin 2012). The typical site of an EM is
on a leg or on an arm (84% of culture confirmed patients) (Strle et al. 2013).
EM  is  the  only  clinical  manifestation  of  LB  which  can  solely  be  used  as  a
basis  of  LB diagnosis  without  confirmatory  laboratory  tests  (Stanek  &  Strle
2003). Other symptoms of LB are not disease-specific and other diseases or
infections have to be ruled out (Stanek et al. 2012).
Figure 11 EM on the ham of the right knee of an adult Finnish female patient with recent Lyme
borreliosis. Diameter of the rash is approximately 10.5 cm. Photo Heidi Sillanpää
Sometimes two or more secondary EM lesions appear (in North American
patients) and a few patients (often children) get lymphocytoma, a typical
manifestation  for  LB,  which  appears  as  a  bluish-red  tumour-like  nodule
usually  at  the  ear  lobe  (children)  or  nipple  (adults)  (Brouqui  et  al.  2004;
Rupprecht  et  al.  2008b;  Stanek  et  al.  2011).  Other  symptoms  besides  EM
include fatigue, arthralgia, myalgia, headache, stiff neck and fever either with
or without chills (Nadelman et al. 1996). Around 60% to 80% of patients with
early Lyme borreliosis manifest with EM. However, some patients (over 10%
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in  Europe)  may  be  asymptomatic  (Steere  2001;  Rizzolli  et  al.  2011).  The
differences between manifestations of LB in European and North American
patients are presented in Table 1.
Table 1. Comparison of manifestations of LB and their prevalence in Europe and Northern
America (Hengge et al. 2003; Stanek et al. 2003; Stanek et al. 2012).
Symptom Europe Northern America
EM Most common, duration of
rash long (2-6 weeks)
Most common, duration of rash
short (median 4 days)
Systemic symptoms Uncommon, more patients
with local symptoms
Common, observed in most
patients
Multiple EM Rare (7%) Common (30%)
ACA Rare Very rare
Lymphocytoma Rare Very rare
LNB More severe radicular pain More meningitis, stiff neck,
headache
LA Uncommon Common
Cardiac LB Very rare Very rare
Ocular manifestations Very rare Very rare
ACA, acrodermatitis chronica atrophicans; EM, erythema migrans; LA, Lyme arthritis; LB, Lyme
borreliosis; LNB, Lyme neuroborreliosis
2.7.2 OTHER MANIFESTATIONS OF LYME BORRELIOSIS
After the acute phase of EM, manifestations of later stages of the disease have
been  traditionally  divided  into  early  disseminated  or  late  Lyme  borreliosis
(Brouqui et al. 2004). This division is more or less theoretical and not always
in agreement with clinical findings (Wormser et al. 2006; Stanek et al. 2012).
It is worth noting that all later stages of Lyme borreliosis can develop without
previous EM (Tijsse-Klasen et al. 2013).
Neuroborreliosis  (LNB)  is  a  group  of  manifestations  in  the  central  or
peripheral nervous system (Strle & Stanek 2009). LNB is primarily an acute
disease;  clinical  manifestations  occur  after  1  to  12  weeks  (Mygland  et  al.
2010; Stanek et al. 2011). In Europe, B. garinii is known for its neurotropism
(van  Dam  et  al.  1993;  Ekerfelt  et  al.  1998;  Strle  et  al.  2006).  Symptoms  of
neuroborreliosis include painful meningoradiculitis with inflamed nerve
roots and lancinating, radicular pain (known as Bannwarth’s syndrome), and
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lymphocytic  meningitis  or  distinct  forms  of  cranial  or  peripheral  neuritis
(Rupprecht et al. 2008b). In patients with Bannwarth’s syndrome, the initial
and maximal radicular involvement is often linked to the location of tick bite
or  EM  and  this  has  led  to  the  hypothesis  that Borrelia spirochaetes could
migrate into the central nervous system along the peripheral nerves or
lymphatic vessels (Rupprecht et al. 2008b). Bannwarth’s syndrome is seen in
European patients (it is very rare in the United States) and it is linked to B.
garinii, whereas in North American patients, the most frequently observed
clinical manifestation of neuroborreliosis is meningitis (Rupprecht et al.
2008b). Facial nerves are frequently affected in neuroborreliosis resulting in
peripheral  facial  palsy  (unilateral  or  bilateral)  (Stanek  &  Strle  2003).
Encephalitis  and  myelitis  are  rarely  seen  and  cerebral  vasculitis  even  more
rarely  (Stanek  et  al.  2012).  Neuroborreliosis  (LNB)  can  be  classified  into
three  classes  according  to  the  duration  of  symptoms,  but  usually
neuroborreliosis is addressed as early and late neuroborreliosis (Oschmann
et al. 1998; Mygland et al. 2010).
Lyme  arthritis  (LA)  is  one  of  the  most  frequent  symptoms  of  LB  in  the
United States,  but this  late manifestation is  less common in Europe (Steere
2001;  Stanek  &  Strle  2003).  It  has  been  characterized  as  intermittent
arthritis  in  one  or  several  large  joints,  presenting  as  swelling  often  in  the
knee, followed by elbow, ankle, shoulder, or hip (Steere 2001; Stanek & Strle
2003).  Inflammation in joints lasts  from a few days to weeks or sometimes
several months or years (Steere et al. 1987).
In  later  stages  of  the  disease,  some  patients  develop  a  skin  condition
called acrodermatitis chronica atrophicans (ACA). ACA develops slowly
starting  from  a  hardly  noticeable  slightly  red-bluish  discolouration  and
oedema on the dorsal  part  of  a  hand,  knee,  or  foot  which then grows larger
slowly over months or years until oedema slowly disappears and atrophy
becomes gradually prominent (Stanek & Strle 2003).  The skin becomes thin
and  wrinkled  and  violet  in  colour.  Some  of  the  patients  have  peripheral
neuropathy, adjacent periarticular nodules or joint subluxation beneath
lesions or combination of  two or more of  these symptoms (Nadelman et  al.
1996;  Stanek  &  Strle  2003).  Some  uncommon  skin  manifestations,  such  as
scleroderma circumscripta and lichen sclerosus et atrophicus, may be caused
by LB, but this association is controversial (Strle & Stanek 2009; Zollinger et
al. 2010; Stanek et al. 2012). Cutaneous B-cell lymphoma has been suspected
to be associated with LB, but again, this association is controversial (Stanek
et al. 2012; Ferreri et al. 2013).
Lyme carditis,  the heart  involvement in LB,  usually  presents as an acute
onset of varying degrees of atrioventricular (I-III) blocks (conduction or
rhythm disturbances) (Steere et al. 1980; Steere 2001; Stanek & Strle 2003;
Strle  &  Stanek  2009).  Sometimes  it  may  be  associated  with  myocarditis  or
pericarditis (Strle & Stanek 2009; Stanek et al. 2012). Cardiac involvement is
observed  in  approximately  5%  of  patients  (Brouqui  et  al.  2004).  Ocular
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manifestations  of  Lyme borreliosis  are  very  rare  and  include  conjunctivitis,
papillitis, episcleritis, keratitis and uveitis (Strle & Stanek 2009).
Co-infections  may  worsen  the  symptoms  of  LB  or  induce  same  kinds  of
symptoms, but clinical data of co-infections is scarce. Some of the possible
co-infections  are  known to  be  spread  via  tick  bites,  such  as  relapsing  fever,
Anaplasmosis (formerly Ehrlichiosis), Rickettsiosis, and Babesiosis.However,
other vectors such as mosquitos and lice can spread these diseases (Brouqui
et al. 2004; Wormser et al. 2006).
Post-Lyme disease syndrome and the possibility of LB becoming a chronic
condition  have  been  widely  discussed  (Feder  et  al.  2007).  Chronic  Lyme
disease is a condition where there is a persistent infection with progressive
symptoms  occurring  for  several  months  or  even  several  years  (Ljostad  &
Mygland 2013). In some of the North American arthritis patients, symptoms
have persisted several years after multiple antibiotic treatments and the
condition has been referred as treatment-resistant arthritis (Steere et al.
1987). In 1998 Gross et al reported that such patients carry HLA-DRB1*0401
allele  with  an  increased  frequency.  This  allele  of  major  histocompability
complex (MHC) has been reported to bind OspA and T cells  (TH1 type) and
such  patients  react  towards  OspA  protein  (Gross  et  al.  1998a;  Gross  et  al.
1998b).  It  is  speculated  that  these  patients  have  developed  an  autoimmune
disease by a cross-reactive response between OspA and a self-antigen (Gross
et al. 1998a). It is known at present that treatment resistant arthritis is
associated  all  together  with  six  T-cell  reactive  HLA  genotypes  (Chen  et  al.
1999;  Steere  &  Angelis  2006).  Molecular  mimicry  has  also  been  thought  to
cause  cross-reactivity  (Steere  et  al.  2001).  In  a  mouse  model,  borrelial
antigenic and inflammatory debris  has been shown to persist  near cartilage
and articular surfaces and slow degradation of these components may lead to
the development of treatment-resistant arthritis (Bockenstedt et al. 2012).
Suspected  chronic  Lyme borreliosis  patients  can  be  divided  roughly  into
four  categories:  1)  patients  with  symptoms  of  unknown  cause  without
evidence of LB, 2) patients with a well-defined disease without relation to LB,
3) patients with symptoms of unknown cause with antibodies against LB but
no  history  of  objective  clinical  findings  consistent  with  LB,  and  4)  patients
with post-Lyme disease syndrome (Feder et al. 2007). The term chronic LB is
sometimes  even  used  when  referred  to  ACA,  which  should  actually  be
referred as late Lyme borreliosis (Stanek et al. 2012).
Diagnostic criteria, prevalence and treatment of chronic LB have caused
conflict  of  opinions.  Those who rely on strict  diagnostic  criteria see chronic
LB  as  a  rare  condition,  whereas  those  who  base  the  diagnosis  on  patient’s
opinion  and  non-specific  subjective  symptoms  consider  chronic  LB  as  a
common condition and risk of public health (Oschmann et al. 1998; Cameron
et al. 2004; Wormser et al. 2006; Wormser et al. 2006; Mygland et al. 2010).
Scientific  debate  on  the  role  of  cystic  forms  of  spirochaetes  causing  LB  is
ongoing (MacDonald 2006; MacDonald 2013; Lantos et al. 2014). Detection
of Borrelia spirochaetes  by  cultivation  of  patient  samples  has  very  low
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sensitivity.  However,  patients  suspected  to  have  chronic  LB  may  have
Borrelia-specific antibodies (IgG) in their blood and patients with chronic
neuroborreliosis  may  have  intrathecal  production  of  antibodies  and
pleocytosis in their cerebrospinal fluid (CSF) (Ljostad & Mygland 2013).
Post-Lyme  disease  syndrome  (PLDS)  may  be  suspected  when  a  patient
has subjective disabling symptoms such as fatigue, musculoskeletal pains,
cognitive dysfunction, or reduced health-related quality of life with duration
of  symptoms longer  than  six  months  (Wormser  et  al.  2006;  Eikeland  et  al.
2011; Eikeland et al. 2012). The cause of PLDS is unknown. According to one
theory, unsuccessful antibiotic treatment might lead to persistent Lyme
borreliosis infection (Ljostad & Mygland 2013). Several studies argue against
this  theory,  such  as  lack  of  accompanying  clinical  signs,  laboratory  test
results,  and  benefits  of  repeated  and  prolonged  courses  of  antibiotics
(Klempner  et  al.  2001;  Krupp  et  al.  2003;  Feder  et  al.  2007;  Fallon  et  al.
2008;  Ljostad  &  Mygland  2010).  Autoimmune  and  psychopathological
phenomena  are  suggested  to  have  an  effect  on  the  development  of  PLDS
(Hassett  et  al.  2008;  Rupprecht  et  al.  2008a;  Ljostad  &  Mygland  2010;
Steere et al. 2011).
2.7.3 BLOOD-BRAIN BARRIER AND NEUROBORRELIOSIS
For normal neuronal activity and function of the brain, neurons in the central
nervous  system  (CNS)  have  to  be  maintained  in  an  optimal
microenvironment (Abbott et al. 2006). For example, the ion balance in the
CNS has  to  be  maintained  and  the  molecular  and  cellular  traffic  across  the
blood-brain barrier (BBB) controlled (Pulzova et al. 2009; Abbott 2013).
Normally, endothelial tissues have small spaces between cells, but in the
brain tight junctions close these spaces between the endothelial cells (Abbott
2013). This is described as theblood-brain barrier (Bentivoglio & Kristensson
2014). To be accurate, there are three different kinds of barriers in the brain
and CNS: the blood-brain barrier (BBB) between microvascular endothelial
cells  and  CNS,  the  blood-CSF  barrier  (BCSFB)  between  epithelium  of  the
choroid plexus and brain,  and the arachnoid barrier  between the arachnoid
epithelium and CNS (Abbott 2013). The barriers of the brain are presented in
Figure 12.
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Figure 12 Barriers of the brain. There are three principal barrier sites between blood and
brain: the blood-brain barrier, blood-CSF barrier and arachnoid barrier (Pulzova et
al. 2009; Abbott 2013).
The BBB is semipermeable in its barrier function and able to respond to a
variety of regulatory signals both from the brain and the blood side (Abbott &
Friedman 2012; Abbott 2013). In the normal homeostatic state (without
inflammation),  the  BBB  is  keeps  certain  molecules  (such  as  toxins),  but
permits  passage  of  others,  including  glucose,  amino  acids,  and  small
peptides.  Ion homeostasis  is  essential  for  proper neurons function (Pulzova
et al. 2009; Abbott 2013). Entry of leucocytes is also regulated and immune
surveillance is allowed at some level for macrophages, dendritic cells, and T-
cells  in  the  perivascular  and  subarachnoid  spaces  (Engelhardt  &  Coisne
2011). The extracellular matrix covers intercellular spaces and can modify
immune reactions, for example via interactions with brain glial and immune
cells (Mohan et al. 2010).
In the brain, immune responses are specialized and slightly different than
in  the  periphery  (Tian  et  al.  2012).  The  capillary  endothelium  is  partially
enveloped  by  pericytes  and  astrocytes.  The  astrocytes  are  in  contact  with
neurons and this  whole complex is  referred as a neurovascular unit  (Abbott
2013). Microglia and astrocytes support and nourish neurons, but also
defendthe CNS against stress and pathogens by up-regulating inflammatory
processes  rapidly  (Bailey  et  al.  2006).  Microglia  and  astrocytes  can  sense
peripheral immune responses through cytokines and chemokines. Microglia
are  also  phagocytes  (as  are  dendritic  cells  and  macrophages)  and  able  to
present foreign antigens to T-cells (Tian et al. 2012). Interestingly, microglia,
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astrocytes, and neuronal cells are capable of synthesizing complement
system  compounds  in  the  brain  (Veerhuis  et  al.  2011).  Proteins  of  the
complement system promote proliferation and regeneration in various
tissues and may have similar functions in the CNS in addition to their role in
recognition  and  killing  of  pathogens  (Ricklin  et  al.  2010;  Veerhuis  et  al.
2011).
Figure 13 Different mechanisms for a pathogen to cross the blood-brain barrier (BBB). In the
Trojan horse mechanism (A), infected phagocytes carry the pathogen across the
BBB by penetrating between tight junctions. In the paracellular mechanism (B),
pathogens travel through tight junctions either with or without disturbing tight
junctions. In the transcellular mechanism (C), pathogens travel through cells by
mechanisms such as ligand-receptor interactions and endocytosis (Pulzova et al.
2009). For Borrelia spirochaetes (D), the mechanism is still unknown. Both
transcellular and paracellular mechanisms are proposed in the literature (Comstock
& Thomas 1989; Szczepanski et al. 1990; Grab et al. 2005).
Pathogenic  bacteria  as  well  as  viruses,  fungi,  and  parasites  have  evolved
different mechanisms to cross the blood-brain barrier (Figure 13) (Rupprecht
et al. 2008b; Pulzova et al. 2009). Many infections interfere with the balance
of CNS and disturb blood-brain barrier functions (Abbott & Friedman 2012).
Inflammatory status induces the production of pro-inflammatory cytokines,
matrix metalloproteases, or reactive oxygen species (free radicals) in
astrocytes  resulting  into  altered  permeability  of  BBB  (Coisne  &  Engelhardt
2011; Tian et al. 2012). Vascular leakage of blood-borne molecules, or
chemokine or cytokine guided migration of inflammatory cells into the CNS,
as well as glial and neuronal apoptosis can cause neurological manifestations
and lead to neurological disorders, such as multiple sclerosis and Alzheimer’s
disease  (Krumbholz  et  al.  2006;  Ramesh  et  al.  2008;  Pulzova  et  al.  2009;
Coisne & Engelhardt 2011). Self-reactive T-cells may have a significant role in
tissue-specific autoimmune diseases such as multiple sclerosis (Engelhardt &
Coisne 2011; Sallusto et al. 2012).
As  neuroborreliosis  is  one  of  the  manifestations  of  LB, Borrelia
spirochaetes  can  cross  the  BBB,  even  though  the  exact  mechanism  is  not
known (Figure 13) (Comstock & Thomas 1989; Szczepanski et al. 1990; Grab
et  al.  2005;  Stanek  et  al.  2012).  The  entry  of Borrelia spirochaetes into the
CSF has been confirmed with culture and PCR techniques (Pfister et al. 1984;
Wilske et  al.  2007).  It  has been suggested that  from the tick bite site  (skin)
the spirochaetes can reach the CNS either through the bloodstream or along
other structures such as peripheral nerves (Rupprecht et al. 2008b).
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Migration of immune cells is regulated by chemokines, a family of around
50 molecules (Blanchet et al. 2012). LNB patients have been observed to have
higher levels of B-cells in their CSF than patients with other CNS infections
(Cepok et al. 2003). B-cells have essential roles in immune responses as they
present  antigens  to  T-cells,  but  also  produce  antibodies  (Murphy  2012).  B-
cell  recruitment  to  CNS  has  been  studied  extensively  and  formation  of
ectopic B-cell follicles with germinal centres in brain meninges has been
reported  at  least  in  multiple  sclerosis  patients  (Serafini  et  al.  2004).  In
studies of chemokines required for B-cell recruitment, the following
observations of neuroborreliosis have been made: B-cell and plasmablast
fractions  are  elevated  and  chemokine  CXCL13  and  CXCL12  levels  and
cytokine BAFF levels are high in the CSF (Krumbholz et al. 2006; Kowarik et
al.  2012).  High  CXCL12,  CXCL13,  and  BAFF  levels  are  associated  with
neuroborreliosis  (CXCL13  has  the  strongest  association),  but  also  to  other
inflammatory  neurological  diseases.  High  CXCL13  levels  were  found  to
correlate significantly with CSF cell count, albumin quotient, intrathecal IgA,
IgM,  and  IgG  synthesis,  B-cell  and  plasmablast  levels,  and  have  reverse
correlation  with  monocyte  levels.  BBB  disturbance  was  described  in  both
studies as a ratio of albumin in CSF and serum (>7.4 x 10-3 for Krumbholz et
al. 2006 and ≥8.0 x 10-3 for Kowarik et al. 2012).
A T-helper type 1 cell (TH1) response appears to dominate in early LNB in
children (Widhe et al. 2005; Henningsson et al. 2011). A TH2 (T-helper type
2) cell response which rapidly follows the TH1 response has been speculated
to account for a more benign course of LNB in children (Widhe et al. 2005).
A  TH1 cell response appears to correlate positively with immune system
mediated killing of the Borrelia spirochaetes (Strle et al. 2014). Recently,
atypical responses of the T-helper cell subpopulation TH17, together with the
cytokine IL-23 have been linked to autoimmune conditions including
rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus,
and  type  I  diabetes  (Kolls  &  Linden  2004;  Stockinger  &  Veldhoen  2007;
Cosmi  et  al.  2008;  Miossec  &  Kolls  2012;  Noack  &  Miossec  2014;  Sie  et  al.
2014). TH17 cells might also have a role in prolonged and severe symptoms in
later stages of Lyme borreliosis, such as neuroborreliosis (Henningsson et al.
2011; Strle et al. 2014). Macrophages have also been shown to participate in
the clearance of CNS infection together with natural killer T-cells (Godfrey &
Berzins 2006; Garg et al. 2009).
2.7.4 LYME BORRELIOSIS IN CHILDREN
Lyme borreliosis symptoms in children are more or less the same as in adults
(Stanek et al. 2012). However, ACA, Bannwarth’s syndrome, and
polyradiculoneuritis  are  not  typical  for  child  patients.  Lymphocytoma  is
more  often  seen  in  children  and  is  usually  in  the  ear  lobe  (Brouqui  et  al.
2004;  Stanek  et  al.  2011;  Stanek  et  al.  2012).  Children  have  a  better
prognosis, symptom duration is shorter, and persistent symptoms are
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observed more rarely (Christen et al. 1993; Berglund et al. 2002; Vazquez et
al. 2003; Skogman et al. 2008b). Typical general symptoms of children and
adolescents with neuroborreliosis are malaise, headache, fatigue, fever, and
neck pain.  Among neurological  symptoms,  facial  palsy is  the most common
followed  by  other  cranial  nerve  paresis  and  meningitis  (Broekhuijsen-van
Henten  et  al.  2010).  Other  neurological  symptoms may  include  myoclonus,
ataxia, vertigo, trochlear palsy, acute transverse myelitis with hemiparesis, or
idiopathic intracranial hypertension (Wilke et al. 2000). In general, LB may
be more difficult to diagnose in children, because some of the symptoms are
typical to other more common early childhood diseases (Christen et al. 1993).
Neuroborreliosis has been shown to cause 30% of acute facial palsy cases in
Finnish  children  and  adolescent  patients  (Kanerva  et  al.  2013).  In  Sweden,
17%  of  124  children  and  adolescent  patients  with  neurological  symptoms
studied were positive for Lyme borreliosis (Sundin et al. 2012).
2.8 LABORATORY DIAGNOSTICS OF LYME
BORRELIOSIS
Diagnosis of LB is based on a combination of clinical evaluation of
manifestations and results of different laboratory tests performed on blood,
CSF  samples,  or  both  (Brouqui  et  al.  2004;  Aguero-Rosenfeld  et  al.  2005;
Wilske  2005).  EM  is  the  only  clinical  manifestation  of  LB  which  does  not
need  a  confirmation  of  diagnosis  with  a  laboratory  test  (Stanek  &  Strle
2003). Culture of B. burgdorferi sensu  lato  or  detection  of  borrelial  DNA
with  polymerase  chain  reaction  (PCR)  from  skin  samples  are  methods  for
direct  demonstration  of  LB infection,  but  they  are  no  longer  recommended
for  routine  laboratory  diagnostics  of  LB  (Wilske  et  al.  2007;  Stanek  et  al.
2012).  Sensitivity  of  culture  or  PCR  is  10-30%  in  acute  LNB  (duration  less
than 2 weeks) and 50-70% in EM, ACA, and LA. Use of other body fluids is
not  recommended  either  for  the  culture  or  PCR  with  the  exception  of
synovial fluid for PCR in arthritis (Wilske et al. 2007). Dark field microscopy
may be used for the direct detection of spirochaetes from patient material.
Common  diagnostic  assays  for  LB  are  ELISA  (or  EIA),  indirect
immunofluorescence assay (IFA) or immunoblotting either with IgM or IgG
or both.,Newer methods such as microarrays, flow cytometric assays, and
enzyme-linked immunospot assay (ELISPOT) have also been tested (Russell
et  al.  1984;  Wilkinson  1984;  Goettner  et  al.  2005;  Coleman  et  al.  2011;
Porwancher et al. 2011; Gerritzen & Brandt 2012; Nordberg et al. 2012; Jin et
al. 2013; Jääskeläinen et al. 2014). Usually Borrelia-specific antibodies are
detected from the blood or CSF samples of patients with two-tier laboratory
testing where the first step is an enzyme-linked immunosorbent assay
(ELISA) or enzyme immunoassay (EIA) (Brouqui et al. 2004; Wormser et al.
2006; Wilske et al. 2007; Stanek et al. 2011). ELISA methods should contain
several borrelial proteins or flagella from several B. burgdorferi sensu  lato
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strains  as  antigens  (Wilske  et  al.  2007).  Since  the  invention  of  ELISA  and
EIA methods in 1960s,  their  development has continued.  Both methods are
based on an immunoassay using an enzyme-linked antibody as a reporter
instead of radioactive labels to detect immunoglobulins (or specific part of it)
in  a  96-well  microtiter  plate  format  (Lequin  2005).  Microtiter  plates  are
coated with a disease-specific antigen, incubated with patient samples.
Antibodies  from  patient  samples  attached  to  antigens  in  the  wells  of
microtiter plates are then detected with enzyme-linked secondary antibodies.
The  addition  of  a  suitable  substrate  leads  to  a  colourimetric  enzyme-
substrate reaction. Optical density (OD) of each well is then measured using
a suitable wavelength of light (Lequin 2005).
Positive  or  borderline  ELISA  test  results  are  usually  confirmed  with  a
secondary assay, such as an immunoblot which can detect both IgM and IgG
antibodies  from  the  same  sample  as  an  ELISA  test  (Wilske  et  al.  2007;
Stanek  et  al.  2012).  A  secondary  assay  is  performed  to  increase  the
specificity. The immunoblot method (usually referred as Western blot (WB))
should  have  high  specificity  of  at  least  95%  (Wilske  et  al.  2007).  In
immunoblotting,  proteins  are  first  attached  to  a  porous  membrane  by
transferring them from a gel using electrophoresis (Gershoni & Palade 1983;
Towbin et al. 1989). Patient samples are then incubated with the membrane
and  antibodies  from  samples  bound  to  proteins  are  then  detected  with
enzyme-linked (or sometimes radiolabeled) secondary antibodies (Gershoni
& Palade 1983; Towbin et al. 1989). A suitable substrate is added to visualize
binding of antibodies either as a light emitting reaction on film or as visible
bands appearing on the immunoblot strips (Towbin et al. 1989).
The sensitivity of different antibody detection methods varies with
different  stages  of  LB  (Wilske  et  al.  2007).  In  early  localized  disease,  IgM
antibodies  are  dominant,  but  the  sensitivity  is  about  20-50%.  Antibody
responses in early stages of disease (EM, acute LNB) may be weak or absent
(Lebech et al. 2000; Steere et al. 2008). In early disseminated infection,
sensitivity  is  70-90%  and  IgM  antibodies  are  dominant,  if  duration  of  the
disease is short (Wilske et al. 2007). In later stages of LB, sensitivity is nearly
100% and IgG antibodies are dominant.  There is  not a  single,  most optimal
test  for  the  diagnosis  of  LB  and  existing  methods  need  to  be  combined  to
achieve  the  highest  possible  efficiency  (Brouqui  et  al.  2004).   It  has  been
noted that persistent antibody responses (both IgM and IgG) towards
Borrelia are measurable 10-20 years after active disease (Kalish et al. 2001).
This complicates the interpretation of laboratory test results of LB patients.
Measurements  of  antibody  responses  are  not  always  indicative  of  active
infection.
The  CSF/serum  index  should  be  determined  when  diagnosing
neuroborreliosis  (Wilske et  al.  2007).  For the ELISA method,  calculating of
antibody index can be done from the OD values by using equation 1 (Hansen
& Lebech 1991).
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(1) 	Calculation of antibody index= OD of CSF
OD of serum
∙(OD of CSF-OD of serum)
An  antibody  index  of  ≥0.3  is  correspondent  to  the  net  OD  differences
exceeding  the  +3SD  (SD  =  standard  deviation)  level  of  the  intra-assay
variation  and  can  therefore  be  considered  as  a  reliable  indicator  of
intrathecal antibody synthesis (Hansen & Lebech 1991).
CSF/serum antibody  index  (AI)  can  also  be  determined  with  equation  2
(Wilske et al. 1986). An antibody index value >2 can be considered indicative
of intrathecal antibody production.
(2)  AI= CSF:serum ratio of specific antibody
CSF:serum ratio of total IgG levels
2.8.1 ANTIGENS FOR THE SERODIAGNOSTICS OF LYME
BORRELIOSIS
Several  borrelial  proteins,  usually  expressed  as  recombinant  proteins  or
sometimes purified from Borrelia spirochaetes (also whole cell  extracts),  as
well as synthetic or recombinant peptides derived from borrelial proteins
have been tested in the serodiagnostics of Lyme borreliosis (Bergström et al.
1991; Hansen 1993; Wilske et al. 1993; Hauser et al. 1998; Panelius et al.
2001; Panelius et al. 2003; Goettner et al. 2005; Wilske et al. 2007; Skogman
et  al.  2008a;  Coleman  &  Pal  2009;  Arnaboldi  et  al.  2013).  Purified,  intact
flagella of Borrelia have  been  used  as  antigens  for  a  long  time  and
commercial assays measuring anti-flagella antibodies are available (Hansen
et al. 1988). If whole cell extracts are used, the Borrelia strains used should
express  OspC  and  DbpA  and  if  possible,  VlsE.  The  use  of  several  strains
should  be  considered  at  least  in  Europe  (Wilske  et  al.  2007;  Hytönen  et  al.
2008). These same proteins are used in several commercial ELISA and
Immunoblot assays aimed for the serodiagnosis of LB. Assays detecting anti-
Borrelia antibodies should contain OspC and DbpA (for detection of anti-
Borrelia IgM  and  IgG,  respectively)  (Wilske  et  al.  2007).  Some  of  the
recombinant proteins and peptides tested or used in the laboratory diagnosis
of LB are presented in Table 2 and Table 3, respectively.
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Table 2. Recombinant protein antigens tested in the serodiagnostics of Lyme borreliosis. Sensitivity and specificity of the respective antigen test are shown as
percentages.
Antigen Sensitivity % Specificity % Remarks References
OspC 7-48 (IgM),
3-6 (IgG)A;
24-84 (IgM+IgG)B;
24-53 (IgM),
6-60 (IgG)C
88 (IgM) A recombinant proteinA-B,
EM, LNB and ACA patientsA,
EM patientsB,
16 protein variants, EM, LNB and LA patientsC
AMathiesen et al. 1998,
BIvanova et al. 2009,
CPanelius et al. 2001
DbpA 43-100 (IgG) 99 (IgG) recombinant proteins, three variants; EM, LA and LNB patients Heikkilä et al. 2002c and
Heikkilä et al. 2003
DbpB 0-64 (IgG) 50 recombinant proteins, three variants; EM, LA and LNB patients Heikkilä et al. 2002a and
Heikkilä et al. 2003
VlsE 36 (IgM),
66 (IgG)D;
63-100E
99 (IgM +
IgG)D;
98E
recombinant protein ELISAD;
recombinant ELISA with goat anti-human Ig (obtained by immunizing with
combination of human IgA, IgD, IgE, IgG, and IgMG;
EM, early disseminated LB,  LA and LNB patientsD,E
DBacon et al. 2003,
ELawrenz et al. 1999
VlsE1 22-100 (IgM+IgG) 96 (IgM+IgG) recombinant protein, flow cytometric assay with polystyrene beads (AtheNA
Multi-Lyte test system) (including PepC10) and WB; EM, LA, early
disseminated LB, myocarditis patients
Porwancher et al. 2011
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BBK32 93-100 (IgG) 93-100 (IgG) recombinant protein, ELISA; EM, LA and LNB patients Heikkilä et al. 2002b and
Heikkilä et al. 2003
Flagella 17-63 (IgM),
24-100 (IgG)A;
29-34 (IgM),
39-45 (IgG)F
89 (IgM)A; commercial assay (formerly Dako, at present Oxoid); EM, LNB and ACA
patientsA,
EM patientsF
AMathiesen et al. 1998,
FLahdenne et al. 2003
FlaA 11-58 (IgM),
6-79 (IgG)
recombinant protein, ELISA; EM, LNB and LA patients Panelius et al. 2001
RevA 3-60 (IgG) 56-100 recombinant protein, WB; LB patients, not specified Brissette et al. 2010
BBK07 34 (IgG) NA recombinant protein, ELISA; patient samples from early and disseminated
stages of LB
Coleman & Pal 2009
BmpA
(P39)
88 (ELISA),
56 (WB)
96 (ELISA)
100 (WB)
recombinant protein, IgG ELISA & WB; LB patients, not specified Fawcett et al. 1993
ACA, acrodermatitis chronica atrophicans; BBK07, a surface exposed lipoprotein of unknown function; BBK32, fibronectin binding protein; BmpA, laminin binding
protein; DbpA/B, decorin binding protein A or B; EM, erythema migrans; FlaA, class of outer layer proteins of flagella; LA, Lyme arthritis; LB, Lyme borreliosis;
LNB, neuroborreliosis; NA, not available; OspC, outer surface protein C; VlsE, variable major protein like sequence expression site; WB, Western blotting
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Table 3. Peptide antigens tested in the serodiagnostics of Lyme borreliosis. Sensitivity and specificity of samples are shown as percentages.
Antigen Sensitivity % Specificity % Remarks References
PepC10 of OspC 30 (IgM),
17 (IgG)A;
36-45 (IgM),
5-8 (IgG)B;
38 (IgM)C;
22-100 (IgG+IgM)D
99 (IgM),
95 (IgG)A;
93 (IgM)B;
99 (IgM)C;
96 (IgG+IgM)D
synthetic peptide 10 aa, ELISAA-C;
EM and LA patientsA,
EM, LNB and ACA patientsB;
early disseminated LB,  LA and LNB
patientsC;
recombinant protein, flow cytometric assay
with polystyrene beads (AtheNA Multi-Lyte
test system) (including VlsE1) and WB; EM,
LA, early disseminated LB, myocarditis
patientsD
AArnaboldi et al. 2013,
BMathiesen et al. 1998,
CBacon et al. 2003;
DPorwancher et al. 2011
OspC1 41 (IgM),
25 (IgG)
99 (IgM),
93 (IgG)
20 aa, serum samples; EM and LA patients Arnaboldi et al. 2013
C6 66 (IgG) 99 (IgG) synthetic peptide 26 aa, ELISA; early
disseminated LB,  LA and LNB patients
Bacon et al. 2003
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VOVO 98 100 recombinant peptide of repeated VlsE-OspC-
VlsE-OspV (VOVO) sequence expressed in
mammalian cells, LIPS (luciferase
immunoprecipitation system) technique
Burbelo et al. 2010
Peptides of
BBK32
73-87 (IgG) 100 (IgG) recombinant peptides, ELISA; EM patients Lahdenne et al. 2003
Peptides of
BBK07
5-90 (IgG) 99 (IgG) WB; LB patients, not specified Coleman et al. 2011
ACA, acrodermatitis chronica atrophicans; BBK07, a surface exposed lipoprotein of unknown function; BBK32, fibronectin binding protein; EM, erythema migrans;
LA, Lyme arthritis; LB, Lyme borreliosis; LNB, neuroborreliosis; NA, not available; OspC, outer surface protein C; WB, Western blotting (immunoblotting)
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2.8.2 CHEMOKINES AND CYTOKINES IN THE DIAGNOSTICS OF
LYME BORRELIOSIS
Assessment of chemokine and cytokine levels has also been introduced to the
laboratory diagnostics of LB (Rupprecht et al. 2009; Cerar et al. 2013). Of the
chemokines or cytokines whose levels have been measured from patient
samples,  CXCL13  has  been  promising,  especially  in  the  laboratory
diagnostics  of  neuroborreliosis  (Rupprecht  et  al.  2005;  Ljostad  &  Mygland
2008;  Rupprecht  et  al.  2009;  Senel  et  al.  2010;  Tjernberg  et  al.  2010;
Schmidt et al. 2011; van Burgel et al. 2011; Wutte et al. 2011; Hytönen et al.
2014).  High  CXCL12,  CXCL13,  and  BAFF  levels  are  associated  with  LNB
(CXCL13  has  the  strongest  association),  but  also  with  other  inflammatory
neurological  diseases.  In  LNB  patients,  high  CXCL13  levels  were  found  to
correlate significantly with CSF cell count, albumin quotient, intrathecal IgA,
IgM,  and  IgG  synthesis,  B-cell  and  plasmablast  levels,  and  inversely  with
monocyte  levels  (Krumbholz  et  al.  2006;  Kowarik  et  al.  2012).  Levels  of
CXCL13, IL-4, IL-5, IL-10, TNF-α, and IFN-γ in the CSF have been shown to
associate with LNB and patients with confirmed LNB had higher levels than
patients  with  suspected  LNB (Cerar  et  al.  2013).  CXCL13  levels  are  high  in
untreated  patients  with  acute  LNB,  but  levels  rapidly  decrease  during
antibiotic  treatment  (Senel  et  al.  2010).  Thus,  CXCL13  levels  can  indicate
active  and  untreated  LB  and  both  the  sensitivity  and  specifity  can  be  high
(94% and 96%, respectively) (Schmidt et al. 2011).
2.9 TREATMENT OF LYME BORRELIOSIS
Lyme  borreliosis  is  treated  with  antibiotics.  The  antibiotic  agent  as  well  as
the  duration  of  treatment  chosen  is  based  on  the  clinical  symptoms  of  the
patient  with  the  help  of  laboratory  test  results  (Stanek  et  al.  2012).
Recommended antibiotics are doxycycline, amoxicillin, acefuroxime axetil,
and phenoxymethylpenicillin taken orally when there are cutaneous
manifestations  or  early  Lyme  arthritis.  In  some  cases,  parental  dosage  is
preferred  (Wormser  et  al.  2006).  For  patients  with  later  manifestations  of
LB,  intravenous  antibiotic  treatment  is  preferred  (Hytönen  et  al.  2008).
Recommendations  for  the  treatment  of  Lyme  borreliosis  are  found  in  the
Finnish handbook “Lääkärin käsikirja” (Handbook for the medical doctor),
among treatment recommendations for common infections and diseases in
Finland  (Table  4)  (Nyman  and  Wahlberg  2014).  There  are  indications  that
intravenous ceftriaxone treatment for 21 days is sufficient in the treatment of
disseminated LB and oral doxycycline treatment instead of intravenous
antibiotics  may  be  effective  enough  (Oksi  et  al.  2007;  Bremell  &  Dotevall.
2014).
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Table 4. Finnish recommendations for the treatment of Lyme borreliosis according to the
Handbook for the medical doctor (Nyman and Wahlberg 2014).
Clinical symptoms
and laboratory findings
Recommendations for treatment
Adults Children
Bite of Ixodes tick without
symptoms of Lyme borreliosis
No antibiotic treatment No antibiotic treatment
EM or lymphocytoma --Amoxicillin or doxycycline
orally for 14 days (sometimes
for 21, if symptoms persistent)
- Amoxicillin dosage:
3 x 500 mg in a day (< 70 kg),
3 x 1 g in a day (> 70 kg),
4 x 500 mg in a day if the
patient is pregnant
- Doxycycline dosage:
2 x100 mg in a day (< 70 kg),
2 x 150 mg in a day (> 70 kg)
- Amoxicillin or doxycycline
orally for 14 days
(sometimes for 21, if
symptoms persistent)
- Amoxicillin dosage:
50 mg/kg in a day divided
into 3 portions
- Doxycycline dosage:
4 mg/kg in a day in 1
portion (for over 8-year-olds
only)
- As a second-line
treatment azithromycin or
cefuroxime axetil may be
used.
Later stages of Lyme borreliosis
(ACA; LA; LNB; cardiac
symptoms, if duration of
symptoms is 4 - 6 weeks and no
local symptoms detected)
- Amoxicillin or doxycycline
orally for 21 days (sometimes
for 28, if symptoms persistent)
- Amoxicillin dosage:
3 x 500 mg in a day (< 70 kg),
3 x 1 g in a day (> 70 kg)
- Doxycycline dosage:
2 x 100 mg in a day (<70 kg),
2 x 150 mg in a day (> 70 kg)
Later stage of Lyme borreliosis
(with long-lasting symptoms
(ACA; LA; LNB; cardiac
symptoms) or local symptoms
detected)
- Ceftriaxone intravenously for
21 days
- Ceftriaxone dosage 1 x 2 g in
a day
ACA, acrodermatitis chronica atrophicans; EM, erythema migrans; LA, Lyme arthritis; LNB,
neuroborreliosis;
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2.10 PREVENTION OF LYME BORRELIOSIS
Due to the vast repertoire of outer membrane expressed proteins in Borrelia
spirochaetes, several proteins including OspC, OspA, OspE, DbpA, BBK32
(=P35), BBK50 (=P37), VlsE, BBA64 have been evaluated for use as antigens
in vaccines against LB (de Silva et al. 1996; Gilmore et al. 1996; Fikrig et al.
1997;  Hanson  et  al.  1998;  Wahlberg  1999;  Liang  et  al.  2001;  Hefty  et  al.
2002a;  Brown  et  al.  2005;  Dai  et  al.  2009;  Brandt  et  al.  2014).  The  OspA
protein  and  its  immunological  features  in  the  diagnosis  of  LB  led  to  the
development of two recombinant OspA-based vaccines, LYMErix
(GlaxoSmithKline, formerly SmithKline Beecham) and ImuLyme (Pasteur
Mérieux  Connaught)  in  the  1990s  (Poland  2011;  Embers  &  Narasimhan
2013).  The  OspA  vaccine  was  shown  to  block  the  transmission  of Borrelia
spirochaetes  from  the  tick  midgut  to  the  mammalian  host  by  inducing
production of antibodies that eliminate spirochaetes already in the midgut of
tick  (de  Silva  et  al.  1996).  In  phase  III  clinical  trials  of  the  OspA  vaccine,
several subjects developed inflammatory arthritis, but there were such
individuals in both vaccine and placebo control groups suggesting that their
arthritis was not induced by OspA vaccine (Steere et al. 1998).
Clinical trials of the LYMErix vaccine had not included participants
younger  than  15  years  old  and  the  Centers  for  Disease  Control  and
Prevention  (CDC)  in  the  United  States  of  America  recommended  it  only  to
persons  aged  between  15  and  70  years  living  and  working  in  woody  and
grassy areas endemic to LB (Sigal et al. 1998; Steere et al. 1998; Benach and
Garcia-Monco 2010; Poland 2011). This meant that children under the age of
15 were not able to receive the vaccine although they were among those with
the  highest  risk  of  getting  this  disease  (Poland  2011).   Other  limitations
observed were that three doses of vaccination were required over a period of
12 months to reach the effective protection against Lyme borreliosis and that
the vaccine only provided protection against North American B. burgdorferi
sensu stricto (efficacy 80%). All these reports, together with class action
lawsuits  and  low  public  demand  for  this  vaccine  lead  to  the  withdrawal  of
LYMErix from the market in 2002 (Poland 2011). The ImuLyme vaccine also
encountered  problems,  such  as  in  licensure  and  was  not  introduced  to  the
United  States  market.  This  together  with  the  problems  what  LYMErix
confronted led to termination of ImuLyme vaccine development (Poland
2011; Embers & Narasimhan 2013).
The  OspA  vaccine  had  some  positive  characteristics  as  well.  Firstly,  it
blocks the transmission of Borrelia from  ticks  to  humans.  Secondly,  it  is
based on a subunit of OspA so that it does not interfere with the diagnostic
methods  used  to  detect  LB.  Finally,  its  target  OspA  is  conserved  enough
within Borrelia species (Embers & Narasimhan 2013). OspC, which has also
been target of vaccine development, has high variability in its epitopes in
different Borrelia species  (Wang  et  al.  1999b;  Earnhart  &  Marconi  2007b).
The  OspC  vaccine  contained  eight  OspC-type-specific  epitopes  (Earnhart  &
53
Marconi  2007a).  The  interest  towards  development  of  LB  vaccine  has
continued and the OspA-based vaccine is in clinical trials again. This time,
the  OspA  vaccine  is  composed  of  three  recombinant  OspA  antigens  which
each contain two different epitopes (detected earlier to be protective) of
OspA from four different Borrelia species  (B. burgdorferi, B. garinii, B.
afzelii, and B. bavariensis) (Wressnigg et al. 2013). A report of Wressnigg et
al  (2013) has already caused a scientific  debate about the safety of  OspA in
vaccines (Lantos 2013; Barrett et al. 2014; Lantos 2014; Stricker & Johnson
2014).
Targeting the vaccine towards the reservoir hosts of LB spirochaetes (such
as the white-footed mouse in the North America) has caught the interest  of
the research field (Embers & Narasimhan 2013; Richer et al. 2014). Richer et
al (2014) reported on their field experiments where they vaccinated white-
footed  mice  with  an  oral  vaccine  (bait)  containing  recombinant  OspA
expressed in Escherichia coli (Fikrig et  al.  1991;  Gomes-Solecki  et  al.  2006;
Richer et al. 2014). The mean prevalence of B. burgdorferi sensu stricto (ss)
in tick nymphs declined 23% in two years (same as one enzootic  cycle of B.
burgdorferi ss)  and 76% in five years (2.5 enzootic  cycles of B. burgdorferi
ss). These kinds of decreases in B. burgdorferi infected ticks might reduce
the risk LB transmission to of humans (Embers & Narasimhan 2013; Richer
et  al.  2014).  A  combination  of  tick  saliva  protein  Salp15  together  with
borrelial OspA have been shown to confer better protection than either alone
against B. burgdorferi infection in a murine model. The same holds true with
a  combination  of  borrelial  DbpA,  BBK32  and  OspC  compared  to  single
antigens (Brown et al. 2005; Dai et al. 2009).
At the moment,  the best  way to prevent LB is  to avoid exposure to ticks
(Wormser et al. 2006; Stanek et al. 2012). In tick-infested environments use
of protective clothing and tick repellents are recommended. The entire body
should be checked for ticks daily and attached ticks removed immediately.
Aims of the study
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3 AIMS OF THE STUDY
The  general  aim  of  this  study  was  to  identify  more  sensitive  and  specific
antigens in the laboratory diagnostics of Lyme borreliosis.
The detailed aims of the studies were:
1. Evaluation of the performance of five IR6 peptide variants from three
Borrelia burgdorferi sensu lato species and the C6 assay in the serodiagnosis
of Lyme borreliosis (Studies I and III).
2.  Evaluation  of  the  performance  of  three  recombinant  decorin  binding
protein A (DbpA) variants and three decorin binding protein B (DbpB)
variants in the diagnostics of adults with neuroborreliosis (Study II).
3.  Evaluation  of  the  performance  of  three  recombinant  decorin  binding
protein  B  (DbpB)  variants  in  the  diagnostics  of  children  with  early
neuroborreliosis (Study V).
4. Evaluation of the diagnostic use of chemokine CXCL13 concentrations
in the CSF of children with early neuroborreliosis (Study IV).
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4 MATERIALS AND METHODS
Materials  and  methods  used  in  the  Studies  I-V  are  described  partly  in  the
original  publications  and  partly  in  some earlier  publications  from members
of  our  research  group  and  co-authors.  Some  details  are  given  here  in  this
thesis  (Heikkilä  et  al.  2002a;  Heikkilä  et  al.  2002c;  Heikkilä  et  al.  2003;
Tjernberg et al. 2007; Skogman et al. 2008a).
4.1 EXPRESSION AND PRODUCTION OF
RECOMBINANT PROTEINS
Decorin binding proteins A and B (DbpA, DbpB) were used as recombinant
proteins produced in Escherichia coli. The cloning of the encoding genes has
been  described  previously  (Heikkilä  et  al.  2002a;  Heikkilä  et  al.  2002c).  In
brief,  a  PCR  reaction  was  performed  to  amplify  the  genes dbpA and dbpB
from three different Borrelia species (B. burgdorferi IA, B. garinii 40 and B.
afzelii A91).  PCR  products  were  cloned  first  into  pCR2.1  TOPO  vectors
(Invitrogen,  Netherlands)  and  sequenced  at  the  Core  Facility  of  Haartman
Institute, University of Helsinki, Finland. A second PCR was performed to
amplify dbpA and dbpB genes  with  primers  including  restriction  enzyme
(RE) recognition sites for BamHI and KpnI enzymes  and  cloned  again  into
pCR2.1  TOPO  vectors.   Recombinant  plasmids  were  purified  and  pCR2.1
TOPO vectors  containing  genes  for  DbpA and  DbpB proteins  were  digested
with  REs,  purified  and  ligated  into  pQE-30  vector  (6xHis-tag)  (Qiagen,
Hilden, Germany) pre-treated with similar REs and finally transformed into
competent E. coli M15 pREP4 host cells.
Details of the production and purification of these recombinant proteins
have been published earlier, however, the methods have been modified
afterwards and these modified steps are described here (Heikkilä et al.
2002a; Heikkilä et al. 2002c). Recombinant E. coli cells cultivated on Luria-
Bertani plates with ampicillin (100 µg/ ml) and kanamycin (25 µg/ml) were
grown  overnight  at  +37°C.  One  bacterial  colony  was  inoculated  into  50  ml
Luria-Bertani  broth  containing  ampicillin  (100  µg/  ml)  and  kanamycin  (25
µg/ml)  and  grown  overnight  at  +37  ºC  with  agitation.  Next,  1.5  litres  of
Luria-Bertani broth containing ampicillin (100 µg/ml) and kanamycin (25
µg/ml)  was  inoculated  and  grown  at  +37  ºC  with  vigorous  agitation  for  3
hours.  Optical  density  (OD)  was  measured  at  600  nm  and  0.7  mM  (final
concentration) of isopropyl-β-D-thiogalactoside (IPTG) was added to induce
the expression of  recombinant proteins,  followed byfurther incubation for 3
hours  at  +37  ºC  with  vigorous  agitation.  Cells  were  harvested  by
centrifugation (Sorvall RC-5B Plus, DuPont, USA) with a GSA rotor at +4°C
for 10 minutes with a relative centrifugal force (RCF) of 10 427 g and washed
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twice with 1 x phosphate buffered saline (PBS) containing 1mM Pefabloc SC
(4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride) (Roche
Diagnostics GmbH, Mannheim, Germany).
4.2 PURIFICATION OF RECOMBINANT PROTEINS
Cells were sonicated in 1 x PBS with 2 mM Pefabloc SC with a Soniprep 150
ultrasonic  disintegrator  (Sanyo,  Japan)  on  ice.  20  rounds  of  sonication  was
performed (20 seconds sonication with 10 second intervals in between).
Sonicated  cells  were  centrifuged  at  15  996  g  at  +4°C  for  5  minutes.  The
supernatant of sonicated cells was verified with SDS-PAGE. Recombinant
proteins  were  purified  first  with  chelating  sepharose  fast  flow  columns
containing Ni2+ ions (Pharmacia, Uppsala, Sweden; Pharmacia is GE
Healthcare at the moment). The expression and the purity of recombinant
proteins were verified with SDS-PAGE using 15% gels.
Afterwards, recombinant proteins were concentrated with Amicon Ultra
Ultracel 10k tubes (Millipore, Billerica, USA) and centrifuged at +8°C at 1 411
g  until  the  desired  volume was  obtained  (approximately  10  to  30  minutes).
The buffer solution was changed into 10 mM diaminopropane pH 8.8 in H2O
(buffer A) using the same Amicon Ultra tubes. A second purification step for
recombinant DbpA and DbpB was performed with high pressure liquid
chromatography (HPLC) using first Poros HQ20 anion exchange columns
(Amersham Pharmacia, Uppsala, Sweden) (Poros HQ20 columns are at
present  products  of  Thermo  Fischer  Scientific  Inc.)  washed  with  buffer  A.
After  the  injection  of  recombinant  DbpA  or  DbpB,  the  column  was  eluted
with a linear gradient from 0% - 100% of 0.5 M NaCl in H2O (buffer B) over
60 minutes at a flow rate of 0.6 ml per minute at room temperature (+21°C)
with 210nm and 280 nm detection.
Elution fractions were verified first with SDS-PAGE, then fractions
containing DbpA or DbpB were pooled together and buffer solution changed
into 2-morpholinoethenesulphonic acid sodium hydroxide (NaOH) buffer pH
5.2  (buffer  C)  with  Amicon  Ultra  Ultracel  10k  tubes  centrifuged  as  above.
Mono  S  HR16/10  cation  exchange  columns  (GE  Healthcare,  Uppsala,
Sweden) were used in next purification step of recombinant DbpA or DbpB.
The  column was  washed  with  buffer  C,  recombinant  proteins  were  injected
and  the  column  was  eluted  with  a  linear  gradient  from  0%  -  100%  of  1  M
NaCl in H2O (buffer D) over 60 minutes at a flow rate of 0.6 ml per minute at
room  temperature  (+21°C)  with  210  nm  and  280  nm  detection.  Purity  of
recombinant protein fractions was verified with SDS-PAGE. Fractions
containing recombinant protein were pooled together, concentrated and
buffer changed into 1 x PBS with 0.06% NaN3 with Amicon Ultra Ultracel 10k
tubes as described above. Purified recombinant proteins were stored at -20°C
in aliquots.
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For the determination of protein concentration, samples were pre-treated
according to Compat-AbleTM Protein Assay Preparation Reagent Set (Pierce,
Rockford,  USA) (Pierce is  at  present part  of  Thermo Fischer Scientific  Inc.)
instructions and protein concentrations were determined according to BCA
Protein Assay Reagent Kit (Pierce, Rockford, USA) instructions.
4.3 SYNTHETIC PEPTIDES
Five synthetic peptides were designed according to NCBI Genbank sequences
of  invariable  region  6  (IR6)  of  VlsE  proteins  from  three  different Borrelia
burgdorferi sensu lato species (Core Facility of Protein Chemistry, Haartman
Institute, University of Helsinki, Finland). All peptides were biotinylated in
their  amino  terminus.  Peptide  purity  was  analysed  with  HPLC  and  mass
spectrometry.  Length  of  the  peptides  was  25  or  26  amino  acids.  Peptide
codes, Borrelia species  and  amino  acid  sequences  of  each  peptide  are
presented in the Table 5. Peptides were diluted in 1 x PBS and stored at -20°C
in aliquots.
Table 5.  Amino acid sequences and strain of origin of five IR6 peptide variants. Amino acids
differing from the P1 sequence in peptides P2-P5 are in bold.
Peptide
code
Strain of origin Amino acid sequence
P1 B. burgdorferi ss Ia Biotin-[H]MKKDDQIAAAIALRGMAKDGKFAVK[OH]
P2 B. garinii IP90 Biotin-[H]MKKDDQIAAAMVLRGMAKDGQFALKD[OH]
P3 B. afzelii ACAIrecombination cassette 3
Biotin-
[H]MKKRNDKIVAAIVLRGVAKDGKFAAA[OH]
P4
 B. afzelii ACAI
recombination cassette 4
Biotin-[H]MKKSDKIAAAIVLRGVAKDGKFAVA[OH]
P5  B. afzelii ACAIrecombination cassette 5
Biotin-
[H]MKKRNDNIAAAIVLRGVAKSGKFAVA[OH]
4.4 PATIENTS AND CONTROLS
Altogether 412 patients were studied. All patients were treated with
antibiotics and samples were taken before start of antibiotic treatment.
Serum samples are presented in Table 6 and CSF samples in Table 8. Serum
samples from clinically diagnosed patients with EM were collected from
Finland,  Sweden,  Slovenia  and  the  United  States.  Clinical  EM  diagnosis  of
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patients from the USA was culture-confirmed (Peltomaa et al. 2003) and of
Finnish samples either culture- or PCR-confirmed. Second serum samples
were taken at convalescence 13-39 days (median 21 days) later (EM samples
from the United States) and 22-70 days (median 41 days) later (EM samples
from Finland). From Swedish patients, second serum samples were taken at
convalescence 2-3 months later and third serum samples 6 months later.  A
sample panel  of  148 Swedish EM patients had been studied earlier  for anti-
borrelial antibodies with the Virotech Borrelia burgdorferi IgG/IgM ELISA
(former Genzyme Virotech (at present Sekisui Virotech GmbH, Rüsselsheim,
Germany) and the Liaison Borrelia CLIA (Chemiluminescent Immunoassay)
(DiaSorin, Saluggia (Vercelli), Italy) (Tjernberg et al. 2007). In study III,
Swedish EM patient samples and healthy controls were also tested with
Virotech Borrelia Ecoline  IgG/IgM  Line  Immunoblot  (formerly  Genzyme
Virotech, at present Sekisui Virotech GmbH, Rüsselsheim, Germany).
Patients  with  clinically  suspected  LNB  were  from  Finland,  Sweden  and
the United States. Serum or CSF samples, or both, were available. Samples of
LNB (facial palsy) patients from the United States were all tested positive for
anti-borrelial  antibodies  both  in  ELISA  and  Western  blot  and  results  were
interpreted  according  to  CDC  guidelines  (Centers  for  Disease  Control  and
Prevention,  1995).  Samples  (both  serum  and  CSF)  of  Finnish  adults  with
clinically diagnosed LNB in Study II were divided into confirmed and
possible (term suspected used in the Study II) LNB. Their clinical diagnosis
of  LNB  was  based  on  the  guidelines  presented  by  the  CDC  (Wharton  et  al.
1990). Confirmed LNB patients had significant anti-flagella IgG (Dako,
Glostrup,  Denmark)  antibodies  in  the  CSF  and  25  patients  of  34  had
lymphocytic pleocytosis. All of the confirmed LNB patients also had elevated
anti-flagella (Dako, Denmark) and anti-VlsE IgG (Enzygnost Lyme link VlsE
IgG ELISA; Dade Behring GmbH., Marburg, Germany) antibodies in serum.
CSF anti-flagella antibodies were defined as significant if the IgG anti-flagella
antibody titre in the CSF was higher than that  of  the serum divided by 400
(the approximate serum IgG/CSF IgG ratio in healthy persons). Patients with
possible  LNB had  no  anti-flagella  antibodies  in  the  CSF,  but  they  had  anti-
flagella IgM or IgG or both antibodies in serum. Patients in the possible LNB
group were all positive in anti-VlsE IgG test.
Samples  from children  with  clinically  suspected  LNB from Sweden were
included in Studies IV (CSF samples) and V (both serum and CSF samples).
LNB child patients were divided into three groups: confirmed LNB, possible
LNB,  and  non-LNB  (not  determined)  (Skogman  et  al.  2008a.).  Confirmed
LNB  patients  had  pleocytosis  in  CSF  and  either  IgM  or  IgG  or  both  anti-
flagella antibodies in CSF. Possible LNB patients had pleocytosis in CSF and
some had either IgM or IgG or both anti-flagella antibodies in serum but no
anti-flagella antibodies in CSF. Non-LNB patients did not have pleocytosis in
CSF or anti-flagella antibodies in CSF, but some of them may have had either
IgM  or  IgG  or  both  anti-flagella  antibodies  in  serum.  IgG  antibody  levels
towards three variants of  recombinant DbpA, three variants of  recombinant
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OspC,  recombinant  BBK32  (one  variant),  and  IR6  peptide  (P2)  had  been
measured previously from these samples (Skogman et al. 2008a). Intrathecal
antibody production of anti-flagella antibodies was calculated from OD
values of the anti-flagella assay with equation 1 (shown in page 43)
LA  patient  samples  (serum)  from  the  United  States  were  from  clinically
diagnosed patients. Samples all tested positive for anti-borrelial antibodies
both in ELISA and Western blot. Results were interpreted according to CDC
guidelines (Centers for Disease Control and Prevention, 1995). Half of the 56
patients were diagnosed to have treatment-responsive arthritis and the other
half treatment-resistant arthritis.
A  total  of  306  serum  control  samples  were  available  from  patients  with
syphilis (SY), Epstein-Barr virus (EBV), Salmonella, or Yersinia
enterocolitica infections, or patients positive for rheumatoid factor (RF+),
anti-streptolysin antibodies (ASO+), anti-nuclear antibodies (ANA+), and
from healthy blood donors (Table 7). 93 CSF control samples were available
from patients with syphilis, neurosyphilis, viral central nervous system
infections,  or  with  other  neurological  diseases  (Table  8).  Control  CSF
samples had no pleocytosis  in CSF and no anti-flagella  antibodies in serum
or CSF. 242 serum and 20 CSF samples from individuals without any proven
infection were used as healthy controls in all five studies.
Optical density (OD) values of the control samples of individuals without
any proven infection were used to calculate the cut-off values (mean of ODs +
2 SD (standard deviation) for CSF samples in studies II and V; mean of ODs
+ 3 SD for sera samples in Studies I,  II  and V).  CSF samples of  34 controls
and 16 healthy individuals were used to calculate cut-off value (mean OD + 3
SD) for CXCL13 immunoassay (Study IV). In study III, 29 healthy individual
samples were excluded due to positive immunoblot test result (Virotech
Borrelia Ecoline IgG/IgMTM Line Immunoblot; (formerly Genzyme Virotech)
at  present  Sekisui  Virotech  GmbH,  Rüsselsheim,  Germany)  and  the
remaining  171  healthy  individual  samples  were  used  to  calculate  the  cut-off
values (mean of ODs + 3 SD) for both IR6 ELISA and C6 assay (C6 in-house
cut-off value (C6 IH)).
Intrathecal  antibody  production  of  antibodies  to  DbpA  and  DbpB  was
assessed  with  comparing  indexes  counted  as  antibody  index  (AI)  and
equation  2  shown  on  page  43  (Study  II)  (Wilske  et  al.  1986).  An  antibody
index value >2 was considered indicative of intrathecal antibody production.
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Table 6.  Serum samples from patients used in Studies I-III and V.
Patients n
age
(years)
sex
(M/F) I II III V
EM patients
Adults with EM (United States) 30A NA NA 30A
Adults with EM (Finland) 22A NA 10/12 22A
Adults and children with EM (Slovenia) 20 3-64 10/10 20
Adults and children with EM (Sweden) 148B 7-84 58/90 148B
LNB patients
Adults with LNB (Finland) 34 NA NA 14 34
Adults with possible LNB (Finland) 22 NA NA 22
Children with LNB (Sweden) 24 2-13 10/14 24
Children with possible LNB (Sweden) 16 4-16 8/8 16
Children with etiology other than LNB (Sweden) 17 4-17 5/12 17
Adults with FP (United States) 31 6-72 16/15 31
LA patients
Adults with LA  (Finland) 14 NA 7/7 14
Adults with treatment-responsive LA (United States) 28 NA NA 28
Adults with treatment-resistant LA (United States) 28 NA NA 28
A two samples from each patient, 1st at diagnosis, 2nd approximately 1 month after diagnosis;
B three samples from each patient, 1st at diagnosis, 2nd after 2-3 months and 3rd after 6 months;
EM, erythema migrans; FP, facial palsy; LA, Lyme arthritis; LNB, neuroborreliosis; NA, not
available;
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Table 7. Control serum samples used in Studies I-III and V. All other samples are from
Finland except 200 healthy individuals used in Study III.
Controls n
age
(years)
sex
(M/F)
controls (n) used in studies
I II III V
Syphilis 10 NA NA 10
RF+ 8 NA NA 8
ASO+ 13 NA NA 13
EBV 11 NA NA 11
ANA+ 12 NA NA 12 10
Salmonella 5 NA NA 5 3
Yersinia enterocolitica 5 NA NA 4 3
Healthy individuals 42 NA NA 20 20 20
Healthy individuals (Sweden) 200A mean 45 100/100 200A
A 171 samples after exclusion of 29 samples due to positive immunoblotting results; ANA+,
positive for anti-nuclear antibodies; ASO+, positive for anti-streptolysin antibodies; EBV, Epstein-
Barr virus; NA, not available; RF+, rheumatoid factor positive;
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Table 8. CSF samples from patients and controls used in Studies II, IV and V.
Patients n
age
(years)
sex
(M/F)
samples (n) used
in studies
II IV V
Adults with LNB (Finland) 34 NA 16/18 34
Adults with possible LNB (Finland) 22 NA NA 22
Children with LNB (Sweden) 24 2-13 10/14 24 24
Children with possible LNB (Sweden) 16 4-16 8/8 16 16
Children with non-LNB (Sweden) 17 4-17 5/12 17 17
Controls (Finland)
Syphilis 14 NA NA 14 1 13
Neurosyphilis 6 NA NA 6
Adults with other neurological diseases such as
viral meningitis or convulsions /epilepsy 33 NA NA 13 20 10
Children with other neurological diseases 20 NA NA 19 13 10
Adults without any proven infection 20 NA NA 20 16 16
LNB, neuroborreliosis; NA, not available;
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4.5 ELISA METHODS
The  method  of  the  in-house  IR6  peptide  ELISA  used  in  this  study  can  be
found  in  the  original  publication  (study  I,  referred  to  in  study  III)  and  has
been  described  previously  (Heikkilä  et  al.  2003).  Methods  of  the  in-house
ELISAs  for  recombinant  DbpA  and  DbpB  (II  and  V)  have  been  described
previously (Heikkilä et  al.  2002a; Heikkilä et  al.  2002c).  Overviews of  both
recombinant DbpA and DbpB protein ELISA and IR6 peptide ELISA are
presented  in  Table  9.  Background  control  wells  without  IR6  peptides  were
used for each sample in IR6 ELISA. Microlon® 600 96-well microtiter plates
of high-binding polystyrene were used (Greiner Bio-One (formerly Greiner)
GmbH, Frickenhausen, Germany). Alkaline phosphatase conjugated rabbit
anti-human IgG (Fcγ fragment specific; cat-no 309-055-008) was used as a
secondary antibody (Jackson ImmunoResearch Laboratories Inc., West
Grove, USA). As a substrate, 4-nitrophenylphosphate (Boehringer
Mannheim, Germany; at the moment F. Hoffman-La Roche Ltd, Basel,
Switzerland) was used. Absorbance was measured with Multiscan
spectrophotometer iEMS Reader MF (Thermo Labsystems, Vantaa, Finland)
at 405 nm wavelength.
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Table 9. ELISA methods for the recombinant decorin binding proteins A and B (DbpA and
DbpB) and for the IR6 peptides.
ELISA method
Assay protocol DbpA and DbpB ELISA IR6 peptide ELISA
Coating of
96-well
microtiter plates
Recombinant DbpA or DbpB 100
µl/well  (conc. 2 μg/ml) in 1 x PBS
with 0.04% NaN3 (incubated 30
minutes with agitation at RT, then
overnight at +4°C)
Recombinant streptavidin (Roche,
Mannheim, Germany) 100 µl/well (conc.
1 µg/ml) in 1 x PBS with 0.04% NaN3
(incubated 30 minutes with agitation at
RT, then overnight at +4°C)
Post-coating None 100 µl/well 1 x PBS with 0.5% HSA and
0.06% NaN3 (incubated 2 hours at
+37°C with agitation)
Washing 0.9%  NaCl  in  H2O with 0.025%
Tween 20; 5 times 300 µl/well
0.9%  NaCl  in  H2O with 0.025% Tween
20; 5 times 300 µl/well
Addition of
peptide antigens
Not done Peptides 100 µl/well (0.2 μg/well; 1
peptide/well) diluted in 1 x PBS with
0.04% Tween 20 and 0.06% NaN3
(incubated 2 hours at RT with agitation)
Washing Not done 0.9%  NaCl  in  H2O with 0.025% Tween
20; 5 times 300 µl/well
Patient samples Samples 100 µl/well diluted 1:100
(serum) or 1:10 (CSF) in 1 x PBS
with 0.04 % Tween 20, 0.04%
NaN3 and 0.5% BSA (incubated 2
hours at RT with agitation)
Samples 100 µl/well diluted 1:100
(serum)  in  1  x  PBS  with  0.5%  HSA,
1mM benzamidine, 0.2mM
phenylmethylsulphonyl fluoride (PMSF),
0.05% Tween 20 and 0.06% NaN3
(incubated 2 hours at RT with agitation)
Washing 0.9%  NaCl  in  H2O with 0.025%
Tween 20; 5 times 300 µl/well
0.9%  NaCl  in  H2O with 0.025% Tween
20; 5 times 300 µl/well
Secondary
antibody with
alkaline
phosphatase
conjugant
Rabbit anti-human IgG antibody
AP conjugated (100 µl/well)
diluted 1:5 000 in 1 x PBS with
0.5% BSA, 0.04 % Tween 20 and
0.04% NaN3 (incubated 2 hours at
RT with agitation)
Rabbit anti-human IgG antibody AP
conjugated (100 µl/well) diluted 1:5 000
in 1 x PBS with 0.5% BSA, 0.04%
Tween 20 and 0.06% NaN3 (incubated 2
hours at RT with agitation)
Washing 0.9%  NaCl  in  H2O with 0.025%
Tween 20; 5 times 300 µl/well
0.9%  NaCl  in  H2O with 0.025% Tween
20; 5 times 300 µl/well
Substrate 4-nitrophenylphosphate diluted
(conc. 4 mg per ml) in 0.5 M
MgCl2 in 0.1 M diethanolamine pH
10, 100 µl/well
4-nitrophenylphosphate diluted (conc. 4
mg per ml) in 0.5 M MgCl2 in  0.1  M
diethanolamine pH 10, 100 µl/well
Detection OD 405 nm after 20 minutes of the
addition of substrate
OD 405 nm after 20 minutes of the
addition of substrate
AP, alkaline phosphatase; BSA, bovine serum albumin; HSA, human serum albumin; OD, optical
density; PBS, phosphate buffered saline; RT, room temperature (+23°C);
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4.5.1 C6 IMMUNOASSAY
The Quick ELISA C6 Borrelia assay (Immunetics, Cambridge, USA) (Studies
I and III) was performed according to the manufacturer’s instructions.
During  the  years  2003  and  2009,  three  slightly  different  Quick  ELISA  C6
Borrelia assays were provided from the manufacturer and in Studies I and III
one  version  (Cat.  No.  DK-E392-096)  was  used.  Shortly,  25  μl  of  sample
diluent and 25 μl  of  patient sample (serum) were added to microplate wells
and  controls  (positive  and  negative)  to  four  wells.  Conjugate  (IgG+IgM;  50
μl)  was  added  to  each  well  and  incubated  with  agitation  for  25  minutes  at
room  temperature  (RT;  +23°C).  Plates  were  washed  manually  with  1  x
diluted  wash  buffer  containing  PBS  and  Tween  20.  Substrate
(tetramethylbenzidine-hydrogen peroxide solution) was added 100 μl/well
and agitated for four minutes at  RT.  Stop solution (1  M sulphuric acid) was
added 100 μl/well and absorbance of microtiter plates measured at 450 nm
wavelength  with  a  multiscan  photometer  iEMS  Reader  MF  (Thermo
Labsystems, Vantaa, Finland). According to the manufacturer’s instructions,
450  nm  OD  values  are  interpreted  such  that  values  <  0.125  were  negative,
values > 0.150 positive, and values in between indeterminate. A modified, in-
house  C6  cut-off  value  (0.0689)  was  tested  in  the  study  III,  based  on  the
mean  OD  value  plus  three  standard  deviations  (SD)  of  171  healthy  blood
donors  without  IgG  bands  in  an  independent  Western  blot.  Calculations  of
positive results were based on either the manufacturer’s cut-off (C6 Imm.) or
the in-house cut-off (C6 IH).
4.6 CXCL13 IMMUNOASSAY
The Quantikine human CXCL13/BLC/BCA-1 immunoassay (R&D Systems,
Inc.,  Minneapolis,  USA)  (Study  IV)  was  performed  according  to  the
manufacturer’s  instructions.  In  brief,  assay  diluent  was  added  to  wells  of
microtiter plates (100 μl/well). BLC/BCA-1 standard (5 000 pg/ml) was
diluted  and  a  standard  series  constituted  with  calibrator  diluent.  CSF
samples were diluted either 1:1  or  1:10 with calibrator diluent.  Samples and
standard series were added to wells (50 μl/well) and the plate was incubated
for 2 hours at RT (+23°C). The plate was washed manually with wash buffer.
BLC/BCA-1 conjugate was added to each well (200 μl/well) and plate
incubated  2  hours  at  RT  and  washed.  Substrate  (tetramethylbenzidine-
hydrogen  peroxide  solution)  was  added  200  μl/well  and  the  plate  was
incubated for 30 min at RT. Stop solution (2 M sulphuric acid) was added 50
μl/well  and  the  absorbance  of  microtiter  plates  was  measured  at  450  nm
wavelength with Multiscan spectrophotometer iEMS Reader MF (Thermo
Labsystems, Vantaa, Finland). Plates were also measured at 540 nm
wavelength and these OD values were subtracted from the values at 450 nm.
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4.7 STATISTICAL DATA ANALYSES
Different versions of Microsoft Excel (Microsoft, Redmont, USA) and
GraphPad Prism (GraphPad Software Inc., La Jolla, USA) software were used
for calculations of standard statistics (Studies I, II, IV, & V). Correlations
(Pearson) were done in the analysis of results of Quantikine’s CXCL13 assay
and of patient’s clinical data (Study IV). Unpaired t-test was used to calculate
differences between sample groups (Study IV). Fischer’s exact two-tailed test
and Mann-Whitney’s U-test of Statistica 7.1 program were used in the Study
III.  Receiver  operating  characteristic  (ROC)  curve  analysis  was  done  with
MedCalc statistical software version 9.4.2.0 (MedCalc, Ostend, Belgium)
(Study III).
4.8 ETHICAL PERMISSIONS
Ethical permissions for the examination of patient samples retrospectively
was  granted  by  the  ethical  committee  of  the  Helsinki  University  Central
Hospital,  Finland  (licence  number  472/E0/01)  for  the  Finnish  samples
(Studies  I,  II,  IV  and  V),  by  the  regional  ethical  board  of  Linköping
University,  Sweden for  the  samples  for  the  EM samples  (Study  III),  and  by
the  Faculty  of  Health  Sciences  at  Linköping  University,  Sweden  for  the
children and adolescent samples (Studies IV and V).
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5 RESULTS
412  serum  samples  and  113  CSF  samples  from  LB  patients  with  different
manifestations  were  studied  in  this  work  (Studies  I-V)  along  with  over  400
control samples (306 serum samples and 96 CSF samples from healthy
individuals and disease controls). Five variants of synthetic IR6 peptides,
three variants of recombinant DbpA, and three variants of recombinant
DbpB  were  used  in  in-house  assays  together  with  the  Quick  ELISA  C6
Borrelia assay (Immunetics, Cambridge, USA) to analyse the samples.
Quantikine human CXCL13/BLC/BCA-1 immunoassay (R&D Systems, Inc.,
Minneapolis,  USA)  was  also  used  for  determination  of  chemokine  CXCL13
levels from the CSF samples of child patients with LNB.
5.1 IR6 PEPTIDES AND C6 IMMUNOASSAY
By the time we started to study the use of IR6 peptides in the laboratory, C6
(=IR6) peptide (26 aa derived from VlsE of B. garinii IP90) was reported to
be  immunogenic  (Liang  &  Philipp  1999;  Liang  et  al.  1999a;  Liang  et  al.
1999b).  By  that  time  it  was  commonly  known  that  in  Europe  at  least  three
different Borrelia burgdorferi sensu  lato  species  were  able  to  cause  LB
(Hubalek  &  Halouzka  1997).  Our  IR6  research  started  first  with  the  P2
peptide (from the B. garinii IP90 VlsE gene) (Heikkilä et al. 2003; Lahdenne
et al. 2003; Panelius et al. 2003; Heikkilä et al. 2005). One of our aims in the
study I was to compare the antibody responses (both IgM and IgG) towards
heterogeneous IR6 peptides (five variants, P1-P5) from three different B.
burgdorferi sensu lato species (Study I).
Serum  samples  from  EM  patients  at  presentation  from  Slovenia  (n=20)
and both at presentation and at convalescence from Finland (n=22) and from
the United States (n=30) were included (Study I). The percentage of positive
EM samples in the IR6 peptide assay (peptides P1-P5) varied between 5-60%
in  IgM  ELISA  and  between  32-97%  in  IgG  ELISA.  When  samples  at
presentation  and  at  convalescence  were  compared,  the  number  of  IgM
positive  samples  decreased  with  Finnish  patients  at  convalescence,  but
increased with patients from the United States. Combination of IgM+IgG
ELISA results increased the percentages of positive samples with different
IR6  peptides  (36-97%  of  samples  were  positive)  (Figure  14).  Analysis  of
results  from  EM  patient  samples  positive  for  at  least  one  of  IR6  peptides
either  in  IgM or  IgG ELISA (Any  of  P1-P5  IgM+IgG)  is  shown in  Figure  15
together  with  the  C6  Immunoassay  results.  The  percentage  of  positive
samples varied between 73-100% (P1-P5) and 45-94% (C6).
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Figure 14 Percentage of positive EM patient samples from Europe and the United States with
five IR6 peptides (P1-P5) as a combination of IgM and IgG ELISA results (Study I).
Figure 15 Percentage of positive EM patient samples from Europe and the United States with
at least one of the IR6 peptides as a combination of IgM and IgG ELISA results
(Any of P1-P5 IgM+IgG) and C6 Immunoassay (Study I).
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In  our  second  study  (Study  III),  we  evaluated  the  use  of  IR6  peptide
variants and C6 Immunoassay with EM patients (n=148; samples taken at
presentation and at convalescence 2-3 months later and 6 months later) and
healthy  individuals  (n=171)  from  an  endemic  region  Kalmar  in  Southern
Sweden.  Three  variants  (P1,  P2,  and  P4)  of  IR6  peptides  were  used  in  the
Study III, because it was decided that only one peptide per Borrelia species
would be included in the study (P4 of three variants (P3-P5) originating from
B. afzelii ACAI).  The  percentage  of  the  positive  samples  in  the  IR6  peptide
ELISA  (IgG)  varied  between  32-46%  at  presentation,  between  32-40%  at
convalescence after 2-3 months, and between 18-27% at convalescence after
six  months  (Figure  16).  For  the  C6  assay,  the  percentage  of  the  positive
samples  was  24%  at  presentation,  20%  at  convalescence  after  2-3  months,
and 14% at convalescence after six months (Figure 16).
Figure 16 Percentage of positive samples for IR6 peptides P1, P2 and P4 in IgG ELISA, C6
Immunoassay, C6 in-house (C6 IH) (C6 Immunoassay results with assessed as
OD/cut-off values) (Study III). Any of P1, P2, P4 or C6 represents a combination of
results from those four assays as sample positive at least one of four assays. From
same patient there were 3 samples taken, 1st at presentation, 2nd at convalescence
after 2-3 months of diagnosis and 3rd at convalescence after 6 months of diagnosis.
When  results  from  IR6  peptides  and  C6  were  combined  together  and
analysed as a combination of all three IR6 variants and C6 (positive with at
least  one  peptide;  Any  of  P1-P5)  using  the  highest  OD/cut-off  value  in
calculations, the percentage of positive samples was 45% at presentation,
43% at  convalescence  after  2-3  months,  and  30% at  convalescence  after  six
months (Figure 16). An in-house cut-off value (mean of OD values of healthy
individuals  +  3  SD)  was  decided  to  calculate  for  C6  Immunoassay  (C6  in-
house)  as  calculated  for  IR6  peptides.  Percentage  of  positive  samples  in  C6
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in-house (C6 IH) assay was 39% at presentation, 28% at convalescence after
2-3 months, and 18% at convalescence after six months (Figure 16). Some of
the 171 healthy individuals used in this study were positive with IR6 peptides
(P1,  P2,  and  P4)  and  C6  IH  (2,  2,  3,  and  5  respectively)  indicating  the
background seropositivity in an endemic area.
In  the  Study  I,  antibodies  (IgM  and  IgG)  towards  IR6  peptide  variants
were also measured with samples from patients with later manifestations of
LB.  Serum  samples  from  patients  with  LNB  from  Finland  (n=14)  and  the
United States (n=31;  all  had facial  palsy)  and from patients with LA (n=14)
from  Finland  and  the  United  States  (n=56;  28  samples  from  patients  with
treatment responsive LA and 28 samples from patients with treatment
resistant LA) were included. The percentage of positive LNB samples varied
between  0-81%  (IgM)  and  90-100%  (IgG)  and  percentage  of  positive  LA
samples  varied  between  7-23% (IgM)  and  92-100% (IgG).  The  combination
of IgM+IgG ELISA results increased the percentages of positive samples with
different  IR6  peptides;  93-100%  of  LNB  samples  and  88-100%  of  LA  were
positives  (Figure  17).  Analysis  of  results  as  LNB  or  LA  patient  samples
positive for at least one of IR6 peptides either in IgM or IgG ELISA (Any of
P1-P5  IgM+IgG)  is  shown  in  Figure  18  together  with  C6  Immunoassay
results. The percentage of positive samples varied between 96-100% (P1-P5)
and 86-100% (C6).
Figure 17 Percentage of positive LNB and LA patient samples from Europe and the United
States with five IR6 peptides (P1-P5) as a combination of IgM and IgG ELISA
results (Study I).
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Figure 18 Percentage of positive LNB and LA patient samples from Europe and the United
States with at least one of the IR6 peptides (Any of P1-P5) as a combination of IgM
and IgG ELISA results and C6 Immunoassay (Study I).
For  the  C6  Immunoassay,  the  sensitivity  of  all  samples  was  79%  and
specificity  100%  (Study  I)  (Table  10).  In  Study  III,  specificity  of  C6
Immunoassay was 100% (as also in the in-house C6).
Table 10. Specificities (%) of the IR6 peptides and C6 Immunoassay in Study I.
Antigen
P1 P2 P3 P4 P5
Any of
P1-P5
C6
IR6 peptide ELISA IgG (Study I) 98 98 94 92 97 83 100
IR6 peptide ELISA IgM (Study I) 81 75 92 86 92 65 -
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5.3 DBPA AND DBPB ELISA
In the studies II  and V we evaluated the use of  recombinant proteins DbpA
(Study  II)  and  DbpB  (Studies  II  and  V)  (adult  patients  in  Study  II,  child
patients  in  Study  V).  Based  on  our  earlier  studies,  it  was  known  that  the
sensitivity  (percentage  of  positive  samples)  of  DbpA  ELISAs  was  50%  in
serum  samples  of  20  child  patients  suspected  to  have  LNB  and  in  serum
samples  of  51  child  patients  with  LA 98% for  DbpA and  77% DbpB ELISAs
(Heikkilä  et  al.  2003;  Heikkilä  et  al.  2005).  In  one  of  our  earlier  studies,
positivity (percentage) of CSF samples of 89 LNB patients in DbpA ELISAs
varied between 65-97% (Panelius et al. 2003).
Adult patients were divided into two groups: confirmed LNB (n=34) and
possible  LNB  (n=22)  (term  suspected  LNB  used  in  Study  II).  Anti-flagella
antibodies were measured from all patients at the diagnosis of LNB. Duration
of  symptoms  (median)  at  presentation  was  30  days  for  confirmed  LNB
patients and 38 days for possible LNB patients; these patients had early LNB.
The percentage of positive samples in recombinant DbpA ELISAs varied
between  65-70%  (CSF)  and  27-74%  (serum)  in  the  confirmed  LB  patient
group and between 14-46% (CSF) and 14-50% (serum) in possible LB patient
group  (Table  11).  The  percentage  of  positive  samples  of  confirmed  LNB
patients in recombinant DbpB ELISAs varied between 32-74% (CSF) and 41-
65%  (serum)  and  samples  of  possible  LNB  patient  group  between  0-9%
(CSF)  and  41-55%  (serum)  (Table  11).  When  the  results  of  the  DbpA  and
DbpB  ELISAs  were  analysed  as  a  combination  of  all  three  variants  of  each
protein  together  (positive  with  at  least  one  DbpA or  DbpB;  any  of  DbpA or
any  of  DbpB),  the  percentage  of  positive  samples  of  Dbp  ELISAs  varied
between 9-100% in CSF and 64-88% in serum (Table 11).  The specificity  of
DbpA ELISAs  (CSF)  was  97% and of  DbpB ELISAs  (CSF)  90%.  Intrathecal
antibody  production  could  be  studied  from  25  (74%)  of  confirmed  LNB
patients  and  from 13  (59%)  of  possible  LNB patients.  Of  these  patients,  20
and 3, respectively, had an anti-flagella antibody index >2.
Child patients with LNB were divided into three groups:  confirmed LNB
(n=24),  possible  LNB  (n=16),  and  non-LNB  (patients  with  etiology  other
than LNB) (n=17). Anti-flagella antibodies were measured from all patients
at  the  diagnosis  of  LNB  prior  to  the  enrolment  of  patients  in  our  earlier
study, where antibody levels to three recombinant DbpA variants, three
recombinant OspC variants, one recombinant variant of BBK32 and one IR6
peptide variant (P2) were measured (Skogman et al. 2008a). Median disease
duration  at  presentation  was  1-2  weeks  for  the  confirmed  LNB  group,  less
than  1  week  for  the  possible  LNB  group,  and  1-2  weeks  for  the  non-LNB
group; these patients had very early LNB. Samples were collected from
children  (aged  2-17  years)  with  clinically  suspected  LNB  living  in  a  highly
endemic area in Sweden.
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Table 11. Percentage of positive samples in the recombinant DbpA or DbpB (IgG) ELISAs,
CSF and serum samples from 56 patients with LNB were included (Study II).
Antigen
 DbpA
afz
DbpA
gar
DbpA
ss
Any
of
DbpA
DbpB
afz
DbpB
gar
DbpB
ss
Any
of
DbpB
Patient group
C
SF
sa
m
pl
es Confirmed LNB 70 67 65 100 32 74 35 79
Possible LNB 50 14 46 73 0 9 0 9
Se
ru
m
sa
m
pl
es Confirmed LNB 27 74 65 88 50 65 41 70
Possible LNB 50 14 32 73 41 55 41 64
LNB, Lyme neuroborreliosis
The  percentage  of  positive  samples  in  the  DbpB  (IgG)  ELISA  varied
between 0-42% in CSF and between 0-46% in serum (Table 12). Most of the
samples were positive to the DbpB variant from B. garinii. Once results were
analysed  as  a  combination  of  all  three  DpbB  variants  together  (sample
positive with at least one of the variants), the percentage of the positive
samples in confirmed LNB group was 42% in CSF and 54% in serum. In the
possible  LNB group  the  percentage  of  positive  samples  was  6% in  CSF and
17% in serum. In the non-LNB group the percentage of positive samples was
18% in serum. All of the CSF samples of the patients in the non-LNB group
were  negative  in  DbpB  ELISA.  The  specificity  of  the  DbpB  assay  was  89%
with  serum  samples  and  95%  with  CSF  samples.  If  DbpB  serum  and  CSF
ELISA results were analysed together, the percentage of positive samples was
71%  for  the  confirmed  LNB  patient  group  and  53%  for  the  confirmed  and
possible LNB groups combined.
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Table 12. Percentage of positive samples in the recombinant DbpB (IgG) ELISA. CSF and
serum samples from 57 children with neuroborreliosis were included (Study V).
Antigen
Patient group
DbpB
afz
DbpB
gar
DbpB
ss
Any of
DbpB
C
SF
sa
m
pl
es
Confirmed LNB 4 42 0 42
Possible LNB 6 6 0 6
Non-LNB 0 0 0 0
Se
ru
m
sa
m
pl
es
Confirmed LNB 17 46 8 54
Possible LNB 0 17 0 17
Non-LNB 12 6 12 18
LNB, Lyme neuroborreliosis
5.4 CXCL13 IMMUNOASSAY
In  the  Study  IV,  we  evaluated  the  use  of  Quantikine  human
CXCL13/BLC/BCA-1 Immunoassay (R&D Systems, Inc., Minneapolis, USA)
in  the  diagnosis  of  child  patients  with  early  LNB.  CXCL13  levels  had  been
proposed  earlier  as  a  marker  of  LNB  (Rupprecht  et  al.  2005;  Senel  et  al.
2010).  CXCL13  has  been  characterized  as  an  essential  chemokine  in  the
recruitment  of  B  cells  to  the  CNS  in  various  inflammatory  neurological
diseases  (Krumbholz  et  al.  2006;  Kowarik  et  al.  2012).  High  CXCL13  levels
have been measured from untreated LNB patients (Senel et al. 2010). Earlier
knowledge  of  CXCL13  levels  in  CSF  of  children  with  early  LNB  was  scarce
(Tjernberg et al. 2010; Wutte et al. 2011).
Child patients (the same panel  of  samples as in Study V) with LNB were
divided into three groups: confirmed LNB (n=24), possible LNB (n=16), and
non LNB (patients with other etiology than LNB) (n=17). CXCL13 levels were
measured only from CSF samples. The percentage of positive samples in the
CXCL13  Immunoassay  was  100%  in  the  confirmed  LNB  group  and  69%  in
the  possible  LNB group  (Study  IV).  CXCL13  concentrations  measured  were
between 162-11864 pg/ml (median 3485 pg/ml) in the confirmed LNB group
and between 16-6249 pg/ml (median 686 pg/ml) in the possible LNB group.
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All  samples  from  the  non-LNB  group  of  patients  were  measured  to  have
lower  CXCL13  concentrations  than  the  cut-off  value  103  pg/ml
(concentrations varied between 14-21 pg/ml, median was 17 pg/ml). The cut-
off value was calculated from the non-LNB and control samples as an average
of values plus 3 SD. The specificity of the CXCL13 assay was 100%.
Discussion
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6 DISCUSSION
Laboratory  diagnostics  of  Lyme  borreliosis  is  often  challenging  (Brouqui  et
al.  2004;  Wormser  et  al.  2006;  Stanek  et  al.  2012).  Even  though EM is  the
most common sign of Lyme borreliosis, some patients do not notice or do
develop  EM,  and  patients  may  not  notice  a  tick  bite  (Berglund  et  al.  1995;
Skogman et al. 2008b; Aucott et al. 2009; Rizzolli et al. 2011). As EM is the
only  clinical  manifestation  of  LB which  can  be  used  as  a  basis  of  a  reliable
clinical diagnosis, laboratory tests are needed to confirm diagnosis.
Manifestations and their duration vary. For example, neuroborreliosis
(especially in children) is sometimes more difficult to diagnose due to
manifestations resembling those of other diseases (Christen et al. 1993).
Development of different symptoms is at least partially due to different
Borrelia burgdorferi sensu lato species. For example, B. afzelii is often
associated with dermal manifestations and B. garinii with neurological
manifestations (Canica et al. 1993; Rijpkema et al. 1997; Ornstein et al. 2001;
Ruzic-Sabljic  et  al.  2001;  Tijsse-Klasen  et  al.  2013).  Some  OspC  types  are
more  often  associated  with  development  of  EM,  indicating  that  some
Borrelia species might be able to cause infection without EM (Tijsse-Klasen
et al.  2013).  As the geographical  distribution of  species varies,  clinical  signs
and  symptoms  of  LB  are  known  to  vary  in  Europe  and  in  North  America
(Steere  2001;  Franke  et  al.  2013).  The  role  of  different  host  animals  and
vectors in the life cycle and virulence of Borrelia, as well as the importance of
migration of host animals to the distribution of Borrelia spirochaetes, should
not  be  neglected  (Comstedt  et  al.  2011;  Vollmer  et  al.  2011;  Franke  et  al.
2013; Vollmer et al. 2013).
Laboratory  tests  are  required  to  confirm  the  clinical  diagnosis  and  rule
out  other  diseases  (Brouqui  et  al.  2004;  Wormser  et  al.  2006;  Wilske  et  al.
2007; Stanek et al. 2012). Routine laboratory testing of LB includes different
kinds  of  methods  which  measure  primarily  antibody  responses  towards
Borrelia antigens in patient samples (serum or CSF). Usually, standard two-
tier testing with ELISA and immunoblotting is used (Aguero-Rosenfeld et al.
2005; Wilske et al. 2007). These assays have their limitations: low sensitivity
and specificity, as only 20-50% of EM patients may have detectable amounts
of antibodies in the traditional flagella assay (Hansen & Asbrink 1989). One
retrospective study presented that 28% of IgM WB results were false positive
(Seriburi  et  al.  2012).  False  negative  results  are  also  possible,  because
Borrelia specific antibodies may not be detectable in early stages of infection
(Brunner 2001; Tylewska-Wierzbanowska & Chmielewski 2002; Wilske et al.
2007; Cerar et al. 2010). Follow-up samples are sometimes needed.
In the development of diagnostic laboratory assays, the goal is to improve
sensitivity  and  specifity.  Our  aim  was  to  search  for  more  sensitive  and
specific antigens for the laboratory diagnostics of LB. Identification of a
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possible  marker  of  active  or  early  infection  was  one  consideration  before
CXCL13 levels were measured. We chose to produce and test species-specific
variant Borrelia antigens (recombinant proteins or synthetic peptides) in
ELISA format. Antigens were produced from three different Borrelia species
in order to better represent the European situation with several Borrelia
species causing LB. This strategy proved to be successful and provided some
novel views and knowledge on the immune responses of humans to Borrelia
spirochaetes.
6.1 IR6 PEPTIDE VARIANTS IMPROVED SENSITIVITY
Soon after the VlsE protein and its variable structure was revealed, invariable
region 6 (IR6) of VlsE was detected to be immunodominant in several studies
(Liang & Philipp 1999; Liang et al. 1999b; Philipp et al. 2001; Marques et al.
2002; Heikkilä et al. 2003; Panelius et al. 2003; Peltomaa et al. 2003). Both
IgM  and  IgG  antibody  levels  to  IR6  peptide  variants  were  tested  in  an  in-
house  ELISA  with  a  large  number  of  samples  from  European  and  North
American patients with different manifestations of LB (Studies I and III).
Overall, the performance of IR6 peptide ELISAs showed at least equal, or in
some  patient  groups,  better  sensitivity  than  the  commercial  C6
Immunoassay. These results suggest that assays using IR6 as an antigen
would  benefit  from  a  combination  of  several  IR6  peptide  variants  covering
the different B. burgdorferi sensu  lato  species.  This  holds  true  even  with
North American patients. In patients with later manifestations of LB, the
sensitivities between the IR6 ELISA and the C6 Immunoassay were very
similar.  By  analysing  the  combined  IgM  and  IgG  ELISA  results,  the
percentage  of  positive  samples  in  IR6  ELISA  was  higher  than  in  the
commercial C6 Immunoassay.
When testing EM patients at presentation and during convalescence, the
C6 Immunoassay and the IR6 peptide ELISAs complemented each other in
terms  of  positivity  rate.  It  has  to  be  kept  in  mind  that  IR6  tests  in  this
particular study (Study III)  were done only with the IR6 IgG assay whereas
commercial  C6  measured  both  IgM and IgG.  Running  the  IR6  peptide  IgM
tests might have improved the overall sensitivity, although the sensitivity of
IR6 peptide IgM ELISA was lower than the sensitivity of IgG assay (Study I).
A clear decline in the percentage of positive samples in the C6 Immunoassay
can be seen in Figure 16, where results of follow-up samples of EM patients
are  presented.  A  similar  decline  in  C6  antibody  levels  in  EM  patients  has
been  reported  earlier  (Philipp  et  al.  2005).  It  is  tempting  to  link  declined
anti-C6 antibody levels to treatment response.
Assays measuring IgM antibodies are always more difficult to develop due
to the fact that IgM antibodies cluster as pentamers with ten binding sites.
The affinity of one binding site is not as good as the affinity binding sites of
IgG antibodies (Mäkelä et al. 1970; Murphy 2012). IgM antibodies produced
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by  naïve  B-cells  are  generated  before  affinity  maturation  and  somatic
hypermutation, which both increase antibody affinity. Primary IgM
pentamers  may  have  non-specific  interactions,  such  as  binding  to  the  plate
surface,  which  may  in  some cases  lead  to  problems  in  the  assay  procedure.
The specificity of IR6 peptide ELISAs was modest compared to the specificity
of  the  C6  Immunoassay,  indicating  that  some  change  or  changes  in  assay
procedure  or  solutions  might  have  improved  the  specificity  of  IR6  peptide
ELISA.
6.2 ANTIBODY RESPONSES TO HETEROGENOUS
DBPA AND DBPB VARIANTS DIFFERED IN LNB
PATIENTS
Decorin binding proteins A and B (DbpA and DbpB) are related proteins and
important adhesion molecules of Borrelia spirochaetes  binding  both  to
decorin and dermatan sulphate (Fischer et al. 2003). DbpA and DbpB differ
in  their  binding  specificity  to  GAGs  and  mammalian  cell  types.  DbpB  has
been  observed  to  promote  binding  to  glial  cells,  whereas  DbpA  blocks
binding of B. burgdorferi ss  to  decorin,  indicating  that  these  proteins
promote cell-type specific attachment to host cells. In addition, the
heterogeneity of DbpA sequences in different B. burgdorferi sensu  lato
strains  has  been  shown  to  affect  binding  activity  (Benoit  et  al.  2011).
Apparently, the strain heterogeneity may affect binding properties of DbpB
as  well,  but  this  has  not  been  studied  properly  (Heikkilä  et  al.  2002a).
Roberts  et  al.  1998  reported  on  highly  identical  DbpB  sequences.  In  that
particular  study,  the  heterogeneity  of  DbpB  was  studied  between  14 B.
burgdorferi ss isolates and only one B. garinii isolate. Identity of DbpB was
reported to be high (between 96-100%). Accordingly, DbpB has been claimed
to  be  well  conserved  (Roberts  et  al.  1998;  Benoit  et  al.  2011;  Groshong  &
Blevins 2014). This is not compatible with our previous observations showing
identity of DbpB sequences between three Borrelia species  to  be  62-67%
(Heikkilä et al. 2002a).
In  the  laboratory  diagnostics  of  LNB,  analysis  of  both  CSF  and  serum
samples is important both for the exclusion of other neurological infections
and diseases, and for the assessment of anti-Borrelia antibodies (Mygland et
al. 2010). Leucocytes are counted from CSF samples (typically 10-1 000
leucocytes per µl) (Oschmann et al. 1998; Mygland et al. 2010). Assessment
of  intrathecally  produced  antibodies  is  usually  done  by  calculating  the
antibody index from CSF and serum quantitative ELISA results (Wilske et al.
2007). The diagnostic sensitivity of the antibody index has been reported to
be  suboptimal  for  patients  with  early  (acute)  LNB  (Ljostad  et  al.  2007).
Patients with early LNB may not have developed Borrelia-specific antibodies
yet.
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In  our  studies,  DbpA  ELISA  was  found  to  be  more  sensitive  than  DbpB
ELISA in the diagnostics of LNB. This is in accordance with our earlier anti-
DbpA  antibody  results  in  children  with  LNB  (Skogman  et  al.  2008a).  The
sensitivity of DbpA ELISA was clearly better in CSF than in serum of patients
with  confirmed  LNB.  However,  in  possible  LNB  patients  the  sensitivity  of
DbpA ELISAs in serum and CSF did not differ so much. Most of the possible
LNB patients had anti-DbpA antibodies in CSF and some of them anti-DbpB
antibodies,  even  though  none  of  them  have  anti-flagella  antibodies  in  CSF.
This may indicate that anti-DbpA antibodies appear earlier than anti-flagella
antibodies in CSF.
Variations  in  DbpA  and  DbpB  amino  acid  sequences  may  result  in
different immunological responses. Regulation of the expression of these
proteins  may  also  differ  during  the  infection.  Long-lasting  up-regulation  of
DbpA  has  been  observed  in  rabbits  infected  with B. burgdorferi B31
spirochaetes  (Crother  et  al.  2004).  This  is  supported  by  our  observation  of
anti-DbpA  antibodies  which  seemed  to  persist  long  time  after  the  early
phases of LNB. Persistence of anti-DbpA antibodies was also observed in our
previous  study  with  LA  patients  (Heikkilä  et  al.  2003).  The  DbpB  variant
from B. garinii performed best among DbpB variants both in sera and CSF.
This might be due to the neurotropism of B. garinii; most of LNB cases are
probably caused by B. garinii in Europe (van Dam et al. 1993; Strle & Stanek
2009).  DbpA  variants  performed  almost  equally  in  the  CSF  ELISA  with
confirmed  LNB  patient  samples,  but  with  suspected  LNB  patient  samples
variants from B. afzelii and B. burgdorferi performed better than B. garinii.
Anti-DbpB antibodies  were  found in  the  CSF from the  majority  of  adult
LNB  patients  (Study  II),  but  only  from  a  minority  of  children  with  LNB
(Study V). This may be due to shorter duration of the disease in children than
in adults, but also the age of the patient may have something to do with the
different immunological response (Tveitnes et al. 2009). Interestingly, the
majority of the DbpB CSF ELISA positive adult patients had short duration of
disease and lymphocytic pleocytosis in the CSF. The same phenomenon was
observed in children as well, although not as clearly. Expression of DbpA and
DbpB  may  vary  during  different  phases  of  LB  and  the  expression  levels  of
DbpA  and  DbpB  in  the  brain  are  not  known.  DbpB  antibodies  without  a
DbpA antibody response in CSF have been detected previously in one study
with early LNB patients, but our results did not support the absence of DbpA
antibodies in CSF (Fikrig et al. 2004).
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6.3 CHEMOKINE CXCL13 LEVELS WERE
SIGNIFICANTLY HIGHER IN CONFIRMED LNB
PATIENTS
The assessment of CXCL13 levels in CSF samples of patients was introduced
to the laboratory diagnostics of LNB some years ago (Rupprecht et al. 2005;
Ljostad & Mygland 2008). CXCL13 (also known as BCA-1, B-cell attracting
chemokine-1)  is  a  chemokine  which  attracts  B-cells  and  is  released  by
dendritic cells usually in lymph nodes, but CXCL13 levels are also associated
with  infections  of  the  central  nervous  system,  such  as  LNB  and  multiple
sclerosis  (Kowarik  et  al.  2012;  Murphy  2012).  CXCL13  levels  correlate  with
both  intrathecal  antibody  production  and  B-  and  T-cell  numbers  in  CSF
(Krumbholz  et  al.  2006).  In  patients  with  early  LNB,  CXCL13  has  been
shown to increase diagnostic sensitivity (Ljostad & Mygland 2008; Tjernberg
et  al.  2010).  CSF  CXCL13  levels  have  also  been  shown  to  decrease
significantly and rapidly after treatment with antibiotics (Senel et al. 2010).
Our  results  on  the  use  of  CXCL13  in  the  diagnostics  of  LNB  in  child
patients were in agreement with earlier observations of CXCL13. Assessment
of  CXCL13  levels  in  CSF may  improve  early  diagnostics  of  LNB at  the  time
when intrathecal antibodies are not yet detectable (Ljostad & Mygland 2008;
Senel et al. 2010; Tjernberg et al. 2010; Schmidt et al. 2011; van Burgel et al.
2011;  Wutte  et  al.  2011).  The  appearance  of  CXCL13  in  the  CSF is  probably
due to the disturbance of the blood-brain barrier (BBB) and strong humoral
immune  response  in  the  CNS,  because  CXCL13  levels  have  been  shown  to
correlate  well  with  CSF  cell  count,  albumin  quotient,  intrathecal  antibody
synthesis, and B-cell and plasmablast levels (Krumbholz et al. 2006; Kowarik
et al. 2012).
Our  results  on  CXCL13  levels  did  not  correlate  with  CSF  cell  count  or
intrathecal anti-flagella titres, but all confirmed LNB patients had intrathecal
antibodies  and  their  CXCL13  levels  were  high.  In  the  possible  LNB  group,
none of the patients had intrathecal antibodies, but most of them (69%) had
elevated  CXCL13  levels  in  their  CSF.  In  children,  the  duration  of  disease  is
short and as such intrathecally produced antibodies were perhaps not yet
detectable. The results indicate that CXCL13 levels may be detectable earlier
than Borrelia-specific antibodies in the CSF of children.
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7 CONCLUSIONS AND FUTURE
ASPECTS
In  conclusion,  inclusion  of  several  IR6  peptides  in  one  assay  may  enhance
the laboratory diagnostics of Lyme borreliosis, especially the sensitivity of the
assay.  Decorin  binding  proteins  A  (DbpA)  and  B  (DbpB)  may  serve  as
supplementary antigens in diagnostic assays, especially as a combination of
several species-specific variants. Assessment of CXCL13 levels may improve
the  diagnostics  of  neuroborreliosis  as  CXCL13  seems  to  be  an  early
immunological marker of infection in CNS.
The  specificity  of  the  ELISA  assays  was  adequate,  but  with  some
methodological adjustments it could have been even better. On the other
hand,  the  choice  of  a  different  assay  format  could  have  improved  both  the
sensitivity and specificity of the antigens tested. For example, flow cytometric
assays or bead-based immunoassays like cytometric bead array or
microarrays could improve the diagnostic performance considerably. In
conventional ELISA and WB assays used in routine diagnostics, antigen
mixtures  or  combinations,  either  several  variants  of  one  antigen  or  several
antigens in one assay or both, are increasingly used. Assessment of various
chemokine and cytokine levels  may also improve the laboratory diagnostics
of Lyme borreliosis in the future.
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